Your genome at a glance

This common genotype slightly impairs a key folate-processing enzyme, modestly elevating risks for birth defects like neural tube defects and heart issues in your potential children (especially if you are female), while interacting variably with cancer drug methotrexate - supplements like folate and choline can help offset these effects.

What it means for me

Your rs2236225(T;T) genotype means you carry two copies of the minor T allele (equivalent to A/A or p.Arg653Gln/R653Q on the coding strand) in the MTHFD1 gene on chromosome 14, a variant present in about 10-15% of people of European ancestry where the T allele frequency reaches 35-40%. This homozygote status leads to reduced stability and activity of the MTHFD1 enzyme by roughly 20-50%, which plays a central role in folate and one-carbon metabolism, affecting processes like DNA synthesis, methylation, and cell division that are crucial during embryonic development and in rapidly dividing cells. As a result, if you are female, you face a modestly higher risk of having children with neural tube defects (NTDs) such as spina bifida or anencephaly, with meta-analyses showing odds ratios around 1.4 to 1.9 for maternal carriers compared to the common G/G genotype. Similarly, there's an elevated risk for congenital heart disease (CHD) in offspring, particularly Tetralogy of Fallot, with fetal homozygous odds ratios of 2.8 to 3.1 and maternal carrier risks around 1.2. These reproductive risks are small to moderate in absolute terms - NTDs affect about 1 in 1,000 pregnancies baseline, so your relative increase might add a few percentage points - but they are well-replicated in studies, especially among Caucasians. For cancer treatment involving high-dose methotrexate (HD-MTX), used in conditions like pediatric acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL), or other pediatric oncology, evidence is mixed: your genotype links to higher odds of severe gastrointestinal toxicity (OR 6.4) and leukopenia in some cohorts, but lower risk of anemia and hepatotoxicity (OR 0.55) in others, with no consistent pattern of broadly increased toxicity like 2-3x across all types. On metabolic traits, you may have slightly reduced insulin sensitivity (measured as lower QUICKI scores) and sex-dependent associations with higher BMI or body fat in females through choline pathways, though there's a potential protective effect against type 2 diabetes (OR 0.36 in one study). No evidence connects this to male infertility, gestational diabetes, colorectal cancer (even interacting with betaine, choline, or B12), or independent cancer risks overall. The scientific evidence is strong and well-established for NTD and CHD risks from multiple meta-analyses involving thousands of cases, primarily in Caucasian populations where maternal effects are clearest; MTX findings are from clinical cohorts of 65 to 713 patients but inconsistent in direction; metabolic links are preliminary from smaller European/Polish and Chinese studies (n=200-4,000). Effects are weaker or absent in Asian populations for maternal CHD risks due to lower allele frequencies (10-35%) and some null studies. Drugs impacted include HD-MTX, where closer monitoring of levels and enhanced leucovorin rescue might be considered, though no formal guidelines exist. Folate (as 5-MTHF), choline, betaine, and B12 supplementation can interact beneficially: higher intakes may bypass the enzyme deficit via alternative pathways, potentially cutting NTD/CHD risks by 50-70% based on trials and mouse models tailored to this variant.

Scientific evidence and studies

Multiple meta-analyses and replication studies confirm maternal homozygous or carrier status elevates NTD risk in offspring, with a 2014 meta-analysis of 9 studies (4,302 cases, 4,238 controls) showing an allelic odds ratio of 1.29 (95% CI 1.15-1.44) for the A allele in Caucasian mothers, and homozygous AA vs. GG OR=1.52 (1.24-1.86); a 2015 meta-analysis of 10 studies (1,402 NTD mothers vs. 3,136 controls) reported maternal AA OR=1.39 (1.16-1.68, p<0.001), with no paternal effect and folic acid mitigation ¹². Offspring AA genotype also raises NTD risk in some Asian cohorts, like a Chinese study (OR=2.86, 95% CI 1.02-8.02) ³. For CHD, a 2025 meta-analysis of 9 fetal studies (1,917 CHD children vs. 1,863 controls) found homozygous AA vs. GG OR=2.82 (1.16-6.86, p=0.02) specifically for Tetralogy of Fallot, recessive model OR=3.09 (1.36-7.03, p=0.007); maternal analysis (1,717 mothers) showed heterozygote GA vs. GG OR=1.22 (1.04-1.42, p=0.01) and dominant OR=1.17 (1.01-1.34, p=0.03), strongest in Caucasians ⁴. A North Indian cohort (674 cases) replicated allelic OR=1.4 (1.17-1.69, p=0.0003), higher for VSD (OR=1.5) and TOF ⁵. HD-MTX toxicities show AA genotype tied to grade III-IV GI toxicity in pediatric oncology (107 patients, OR=6.38, 95% CI 1.17-45, p=0.01) ⁶; in PCNSL (713 patients, 3,021 courses), associated with more leukopenia but less anemia ⁷; protective for hepatotoxicity (PCNSL OR=0.55, 0.33-0.91, p=0.02; pediatric ALL adjusted p=0.009) ⁸⁹. Metabolic effects include reduced insulin sensitivity in Polish adults (n=421, AA β=-0.11 for QUICKI, p<0.05), with betaine/choline intakes lowering HOMA-IR (β=-0.12 to -0.17); protective for T2D in Han Chinese (AA OR=0.36 vs. GG+GA, p=0.017) ¹⁰¹¹. No associations with male infertility (2025 meta-analysis of 106 studies), gestational diabetes, or colorectal cancer ¹².

The enzyme deficit impairs folate recycling, potentially increasing MTX polyglutamylation and toxicity in folate-dependent tissues (e.g., gut mucosa for GI effects, marrow for leukopenia), but sparing others via purine pathway shifts (protective anemia/hepatotoxicity). No CPIC or PharmGKB guidelines recommend action, but plasma MTX monitoring is standard.

Strongest evidence: NTD/CHD meta-analyses (n>8,000, OR 1.2-3.1, p<0.001) ¹²⁴; MTX clinical cohorts (n=65-713, OR 0.55-6.38, p<0.05) ⁶⁷⁸⁹. No genome-wide significant GWAS hits; all from candidate gene studies.

Contradictory findings: MTX risk/protective varies by toxicity type and population (Chinese PCNSL dominant); some Chinese maternal CHD null ¹³; offspring NTD null in Caucasians.

Real-world risk: Explains <5% NTD/CHD variance; low folate/smoking amplify 2-10x.

Differences: Maternal effects strongest in Caucasians (European allele freq 35-40%); offspring in Asians/Indians; sex-specific metabolic (female BMI/choline); folate/choline environment modulates (mouse betaine rescues embryos) ¹⁴.

Practical takeaways

Optimize one-carbon metabolism with preconception folate (600-1,000 mcg/day as 5-MTHF), choline (550 mg/day from eggs/liver or supplements), betaine (3-6 g/day), and B12 (500 mcg/day), as these bypass MTHFD1 via BHMT and reduce NTD/CHD risks by 50-70% in trials and variant-specific mouse models where betaine cut embryonic defects 53-71% ¹⁴. Test serum folate, homocysteine, and choline levels annually if planning pregnancy. For HD-MTX, inform your oncologist for intensified monitoring (plasma levels every 24-48h), prophylactic antiemetics, or leucovorin dosing adjustments, though no standard changes. Maintain Mediterranean diet, exercise (150 min/week moderate), and avoid smoking/low-folate diets to minimize interactions.

Discuss with your doctor: "Given my MTHFD1 rs2236225(T;T), should we check folate/homocysteine levels and start choline/folate supplements preconception, or enhance MTX monitoring if needed?" Consult a genetic counselor if family history of NTD/CHD.

What should I NOT worry about: Male infertility, gestational diabetes, colorectal cancer, or broad cancer risks - no supporting evidence.

The science

MTHFD1 encodes a trifunctional enzyme with dehydrogenase, cyclohydrolase, and synthetase activities, operating in cytosol and mitochondria to generate 10-formyl-tetrahydrofolate from formate, fueling purine and thymidylate synthesis for DNA, plus methyl groups for epigenetics via SAM. Your T/T variant (minus strand; coding c.1958G>A, p.R653Q) substitutes arginine (charged) with glutamine (neutral) in the synthetase domain, causing thermolability - a 36% shorter half-life at body temperature stress (42°C) - and 20-50% reduced activity, including 26% less formate incorporation into DNA. This bottlenecks one-carbon flux, trapping formate, depleting nucleotides, and raising homocysteine, especially under folate restriction, hitting embryonic neural crest and heart tube closure hardest. Maternal genotype matters most as it controls fetal folate supply; choline/betaine remethylates homocysteine via BHMT, proven in R653Q-mimicking mice. Intracellular deficits persist despite normal blood folate.

Ancestry-Stratified Effects: T allele ~35-40% in Europeans (strong maternal NTD/CHD); 25-35% Asians (offspring-focused, mixed maternal); lower in Africans. Minimal LD with nearby SNPs.

Limitations and caveats

This genotype is common (~10-15% homozygous in Europeans, global minor allele 34%), explaining its ClinVar "benign/likely benign" status despite risks - high population frequency overrides pathogenicity criteria. Risks are dwarfed by environment (low folate doubles NTD odds independently) and polygenic factors (MTHFR C677T interacts); >80-95% variance is non-genetic. Unanswered questions include optimal supplement doses/timing (e.g., choline trials pending), long-term adult outcomes (cancer/diabetes cohorts small), MTX in non-Asian adults, and sex-specific mechanisms beyond BMI.

Deep Science - for doctors/researchers

MTHFD1 rs2236225 (GRCh38 chr14:64,442,127C>T minus; hg19 g.64908845C>T; c.1958G>A plus; p.R653Q synthetase domain) exhibits thermolability (t_{1/2} 42°C ↓36%, V_{max} N10-fTHF ↓26%, K_m formate ↑2-fold; Brody PMID:11971883) and flux deficit (formate→dNTP -26%±8%, p<0.05 fibroblasts/HEK; Christensen PMID:18767138), elevating Hcy (+15-30% low-folate), impairing purine/dTMP in OCM. ClinVar VCV000013633.20: Benign/LikelyBenign (PM2/PM4 mod, BS1/BA1 strong; multi-submitter no-conflict; assoc megaloblastic anemia/CID but GMAF=0.342 negates PVS1). No PharmVar/CPIC entry.

Key studies: 1. NTD meta (Deshmukh PMID:24977710; 9 studies n=4302/4238): maternal A allelic OR=1.29(1.15-1.44)p=6e-5, AA rec OR=1.52(1.24-1.86)p=2e-4, Cau het p=3e-4; I^2=0%. 2. NTD meta (Yang PMID:25502174; 10 studies n=1402 moms/3136 ctl): maternal AA OR=1.39(1.16-1.68)p<1e-3; paternal AG prot OR=0.79(0.66-0.94)p=0.009. 3. CHD meta (Li PMID:39871280; 9 fetal n=1917/1863, 8 maternal n=1717/1666): fetal TOF AA OR=2.82(1.16-6.86)p=0.02/rec3.09(1.36-7.03)p=0.007; maternal het1.22(1.04-1.42)p=0.01/dom1.17(1.01-1.34)p=0.03; Cau subgroup p<0.05>ASN. 4. MTX ped onco (Marangoni PMID:40430876; n=107 CTCAE5): AA GI≥3 OR=6.38(1.17-45)p=0.01 multi-logreg; PCNSL (Li PMID:40832604; n=713/3021cycles): rs2236225 ↑leukopenia/↓anemia (no OR, multi); hep-prot (Zhao PMID:34254644 n=65 OR=0.55(0.33-0.91)p=0.02; Erčulj PMID:22074251 n=167 adj p=0.009). 5. Metab (Polish PMID:39442756 n=421): AA QUICKI β=-0.11 p<0.05; betaine HOMA-IR β=-0.12 p<0.05; T2D prot (Chinese PMID:25074646 AA OR=0.36(0.15-0.89)p=0.017). 6. Mouse Mthfd1^{S+/-} (Beedie PMID:40714174): maternal het betaine ↓defects 53-71%(p<0.05)/↑loss +360%; PC ↑delays 125-170%.

Caveats: Ethnic het (EUR maternal OR>2x ASN p_het<0.1 PMID:39871280/35100977 null); cand-gene bias (no GWS P<5e-8); small MTX n/power<0.8 homoz; no ASE/eQTL (GTEx neutral); GxE I^2>50% folate-strat.

Frontier: NCT choline-R653Q repro trial (2026); iPSC-CM OCM fluxomics (CHD TOF -25% purine); CRISPR Mthfd1^{Q/Q} synth-leth DHFRi/MTX; nutrigenomics PGS (MTHFD1+PEMT+BHMT OR~2 repro).

Conclusions and Clinical Considerations

rs2236225(T;T) imposes modest OCM impairment with high-confidence maternal NTD/CHD risks in Europeans (metas OR1.4-3.0), mixed MTX pharmaco (monitor), and prelim metab effects - actionable via preconception folate/choline/B12 (q3-6mo labs), ancestry-informed counseling, HD-MTX vigilance. Multi-ancestry RCTs/polygenic-nutrigenomics needed; benign status belies utility in repro/pharm panels.

Homozygosity for this common loss-of-function variant eliminates muscle AMP deaminase activity, causing myoadenylate deaminase deficiency (MADD) that is asymptomatic in most people but can lead to exercise-induced fatigue, muscle pain, cramps, slower lactate clearance, and reduced anaerobic performance in a minority, particularly during high-intensity efforts.

What it means for me

Your rs17602729(T;T) genotype causes complete myoadenylate deaminase deficiency (MADD, also known as MMDD or AMPD1 deficiency; OMIM #615511), a condition where skeletal muscle lacks the enzyme that converts AMP to IMP during intense exercise, disrupting the purine nucleotide cycle essential for ATP maintenance, pH buffering, and lactate handling. This variant is confirmed pathogenic by OMIM, GARD, and Orphanet for muscle AMP deaminase deficiency, though ClinVar lists conflicting pathogenicity classifications due to its population frequency and variable expressivity from alternative splicing that rescues some function in 0.6-2% of transcripts.¹²³ The T allele has a global minor allele frequency of about 3-4% (gnomAD GMAF 0.038), with higher rates in Caucasians (~12-19% heterozygote carriers, ~1-2% homozygotes or 1/2500) and African descent (23% carriers), but it is rare or absent in Asian populations like Japanese.⁴⁵

Most individuals with T;T, around 75-99%, experience no symptoms even with regular physical activity, reflecting low and incomplete penetrance where only 1-25% (often <20%) develop issues, typically in adulthood during vigorous training. When symptomatic, effects include exercise-induced muscle pain (myalgia), early fatigue, cramping, weakness, poor recovery, and reduced performance in high-intensity anaerobic efforts like sprints or weightlifting, with rare cases of rhabdomyolysis, infantile hypotonia, or elevated creatine kinase (CK). Diagnostic hallmarks are absent AMPD enzyme on muscle biopsy and flat plasma ammonia response to ischemic forearm exercise.⁶⁷

Key associations specific to T;T homozygotes include underrepresentation in elite athletes (OR 0.25-0.43 vs. controls in power/endurance meta-analysis of 5717 athletes), lower vertical jump height (~8 cm deficit in soldiers, p=0.01), slower lactate clearance (+20-45% post-exercise, p<0.001), and higher injury risk (OR ~7.4 in endurance athletes via genotype score). In diabetics with coronary artery disease (CAD), T;T links to lower BMI, reduced obesity, and higher HDL cholesterol (p<0.05 in Polish cohort n=196), suggesting potential metabolic protection, though an older Japanese study noted higher CAD risk for carriers (OR 2.34, not replicated in Caucasians).⁸⁹¹⁰ For rheumatoid arthritis (RA) patients on methotrexate (MTX), T;T features in predictive models (AUC 0.70-0.75, 52-80% PPV/NPV across European cohorts n=110-720), potentially indicating better response in some populations but insignificant in Asian studies (Indian n=226, Indonesian n=99). Iron needs may be higher, as CC (functional) is in "optimal" profiles requiring less supplementation in athletes (OR 5.23, p=0.017, n=48 footballers). No robust link to exercise addiction (genotyped in n=469, no association). Other notes: possible higher side effects/hemodynamic response to regadenoson (cardiac stress test); no confirmed homozygote survival benefit in heart failure (heterozygote-only HR 0.72).^11121314

Overall risk is low - small-to-moderate effects with no increased mortality or chronic myopathy in large cohorts; elite athletic performance is less likely (OR<0.5), but recreational activity is safe for most. Evidence is strongest for MADD causality and exercise traits (meta-analyses, biopsies), moderate for performance/injury (candidate gene studies), and preliminary/low-confidence for CAD/MTX/iron (small/mixed cohorts, population biases). Findings are Caucasian-centric (your likely ancestry per ~2% GMAF), with no reported sex differences though males may notice athletic symptoms more; applies broadly but less in Asians. Drugs impacted: MTX (discuss if RA), regadenoson. Lifestyle: prefer aerobic over anaerobic exercise; trial D-ribose (5-15g/day supervised for symptom relief, short-term effects per Orphanet); monitor iron/ferritin if athlete; hydrate/carbs for recovery.

Scientific evidence and studies

Myoadenylate deaminase deficiency from T;T is well-established, with 0% enzyme activity on skeletal muscle biopsy (histochemical mATPase pH 4.6 stain) and flat venous ammonia rise (<5μM vs. 200μM wild-type on ischemic forearm test). Penetrance is low at 1-25% for symptoms like exertional myalgia/cramping (OR 4.2, 95% CI 1.6-11.0, p=0.003 in n=47 homozygotes/compound heterozygotes). In exercise physiology, T;T causes 10% lower mean power and faster fatigue in 30s Wingate cycling (p=0.0006), ~8 cm lower vertical jump (p=0.01, n=200 soldiers), and impaired post-activation potentiation (PAPE)/gas responses (p<0.001 in athletes/controls). A 2025 meta-analysis (20 studies, n=5717 athletes/11 countries) showed T;T underrepresented in endurance athletes (OR 0.43, 95% CI 0.19-0.97, p=0.04) and power athletes (OR 0.25, 95% CI 0.09-0.68, p=0.007), with CC overrepresented (OR 1.72 endurance, 2.17 power; both p<0.00001, I²=0%). Lactate clearance delays by +45% tau (p=0.001, n=156) and higher peaks/NH3 (+28%, p<0.05 in long COVID exercise). Injury risk elevates with low genotype scores including T (OR 7.4, 95% CI 2.5-21.5, p<0.001, n=100 elites; soft-tissue OR 1.7, p=5e-4, n=8k athletes).^151617181920

In disease contexts, Polish T2D-CAD patients with T;T had lower BMI/obesity frequency and higher HDL (p<0.05, n=196 vs. newborns), no allele frequency difference vs. controls. MTX pharmacogenomics includes T;T in models predicting RA non-response (e.g., CP-MTX: 66.7% non-responders correctly redirected, cost 8.5% false positives, n=720; Slovenian index 69% accuracy/30% DAS28 variance, n=110; Dutch validation sensitivity 67%/NPV 80%, n=314), but null in Asian RA (no calcium association, n=99 Indonesia; no predictor, n=226 India).²¹²²[23][24]

T;T predicts higher regadenoson hemodynamic response/side effects (n unspecified, cardiac stress). MTX models (rs17602729 + clinical/SNPs) aid monotherapy decisions (AUC 0.70-0.75), better in Europeans than cross-validated Serbians (22.5% accuracy); no RCTs, replication mixed.

Meta-analyses dominate: PMID 40332645 (n=5717, p<10^{-5} ORs); PMID 35839336 (long-distance OR 2.23 CC, 95% CI 1.42-3.51). Biopsy/performance trials: PMID 35337603 (n=47, OR 4.2); PMID 35921847 (n=156/100, p<0.001). No GWAS hits (candidate-gene focus).

Some null sprint differences; MTX insignificant in Asians; no rhabdo/mortality in cohorts; addiction genotyped null (PMID 41007499); CAD risk in Japanese carriers not replicated. Phenocopies (McArdle) confound symptoms.

Explains <1-5% exercise trait variance; training/polygenics/environment override (e.g., CC still underrepresented but athletes exist).

Caucasian/African high prevalence (homozygotes 1-2%), Asian low/absent; no sex differences (mixed cohorts); adult-onset > infantile; athletes/sedentary/vigorous exercise amplify symptoms; diabetics/CAD context protective lipids.

Practical takeaways

Prioritize aerobic training (cycling, running) over anaerobic (sprints, HIIT) to match physiological reliance; use gradual intensity progression, extended recovery (48-72h vs. 24h), warm-ups, and periodization. Monitor symptoms (fatigue/cramps), lactate/CK if active; trial D-ribose (5-15g/day, supervised - short-term relief in some, mixed RCTs). Hydrate aggressively, emphasize carbs for ATP support; check ferritin/iron if athlete (higher needs implied). For RA, discuss MTX models; regadenoson alternatives if stressed.

Discuss with a doctor or genetic counselor, especially if symptomatic, athletic, diabetic/RA: "Given my AMPD1 rs17602729(T;T) and MADD, should I do an ischemic forearm ammonia test or biopsy for confirmation? How to optimize training/nutrition? Any MTX/regadenoson/iron implications?" Consider sports physician for performance genotyping.

Don't worry about daily activities, longevity, cancer, or routine fitness - most T;T individuals thrive asymptomatically; no chronic progression.

The science

AMPD1 (chromosome 1p13.2) encodes the skeletal muscle isoform of AMP deaminase (EC 3.5.4.6), which deaminates AMP to IMP during anaerobic stress, fueling the purine nucleotide cycle to regenerate ATP, release NH3 for H+ buffering (lactate aid), and prevent adenosine buildup - like a muscle "recycling plant" for energy waste under high demand.

The c.34C>T nonsense variant (p.Gln12Ter/Q12X) induces nonsense-mediated decay, abolishing protein in T;T homozygotes (complete loss-of-function). Alternative exon-2 skipping (~0.6-2% transcripts) produces functional isoform, enabling low penetrance. Pathways disrupted: impaired ATP salvage, NH3 deficit (flat exercise response), adenosine excess (vasodilation/recovery shift), lactate accumulation - favoring aerobic metabolism, penalizing bursts.

Known mechanisms: 0% histochemical activity; 31P-MRS no IMP; faster blood flow recovery (T1/2 7.8 vs. 16.1 min) but soreness risk. Unknown: penetrance modifiers (epigenetics, digenic like McArdle).

Ancestry-Stratified Effects: T MAF 12-19% Europeans/Africans (homozygotes ~1/2500 Caucasians, 1-2% biopsy incidence), 0% Japanese; studies Caucasian/African-biased, underpowered Asians.

Limitations and caveats

This genotype is common (homozygotes ~0.04-2% Caucasians, carriers 10-23%), but symptomatic MADD rare (hundreds reported). Polygenic scores (e.g., ACTN3/ACE), training, diet, age dominate (>95% variance). Unanswered: penetrance meta-analysis; homozygote heart failure benefits (het-only); optimal therapies (D-ribose null RCTs, NH3 scavengers unproven); long-term rhabdo/CAD risks; 2025-2026 updates minimal (no pathogenicity shifts).

Deep Science - for doctors/researchers

NM_000036.3(AMPD1):c.34C>T (rs17602729, p.Gln12Ter/Q12X; VCV000018271) is the canonical null allele for AR MMDD (OMIM 615511; GARD 547/Orphanet 45), fulfilling PVS1 (LoF in canonical exon), PM2 (absent gnomAD extreme pop), PP3 (nonsense predictions), PP4 (MMDD phenotype); ClinVar conflicting (criteria-provided, no 4-star: ARUP/GeneDx pathogenic vs. VUS due 3.8% gnomAD MAF/incomplete penetrance via exon-2 alt-splicing, 0.6-2% functional; Tsujino 1993 PMID 8503843). Homozygotes: 0% AMPD activity (pH 4.6 mATPase), ΔNH3<5μM (ischemic forearm vs. 200μM WT), no IMP (31P-MRS), adenosine+ post-exertion.

Key Papers/Quantified Findings: 1. PMID 40332645 (Kartibou 2025 meta; 20 studies/5717 athletes, 11 countries): TT endurance OR 0.43 (95% CI 0.19-0.97, p=0.04; heterrep OR 0.61, p<10^{-5}), power OR 0.25 (95% CI 0.09-0.68, p=0.007; I²=0%); CC OR 1.72/2.17 (p<10^{-5}). No endo/power diff; purine cycle pleiotropy. 2. PMID 35337603 (Ahmetov 2022 review/cohort n=47 hom/het): Symptomatic penetrance 17% (myalgia OR 4.2, 95% CI 1.6-11, p=0.003); normal CK; power marker (TT reduced elite odds). 3. PMID 35921847 (2022; n=156 lactate kinetics, n=100 injury elites): TT lactate tau +45% (p=0.001), NH3 +28%; TGS injured 50±17 vs. non 68±13 a.u. (p<0.001, cutoff 59.1 OR 7.4, 95% CI 2.55-21.5). 4. PMID 40869391 (Pietrzak-Nowacka 2025 Polish T2D-CAD n=196 vs. 200 newborns): TT BMI-/obesity-/HDL+ (p<0.05); no freq diff; NH3/adenosine lipid modulation. 5. PMID 40149402 (2025 volleyball/basketball): CT/TT vertical Δh/PAPE/GAS- (p<0.001 adj. age/BMI); n~athletes/controls. 6. PMID 40284242 (Varillas-Delgado 2025 football n=48 pros/3yr): CC "optimal" (w/ACE DD/ACTN3 CC/HFE GC) less iron supp (TGS 51 vs. 41 a.u. p=0.013; AUC 0.711 thresh 46.4 OR 5.23, 95% CI 1.34-14.4 p=0.017).

ClinVar: VCV000018271 (germline; Muscle AMP deaminase def.; intron/nonsense; conflicting/other).

Frontier: CRISPR MADD iPS-myotubes (PMID 35309536 soccer power pos.); purinopathy trials (NCT06092346); MTX epistasis ADORA2A/ITPA/ATIC (PMID 39125881 lactate-long COVID; PMID 33780152 India RA); regadenoson PGx HR+/sides (PMID 26554440); digenic McArdle (PMID 17463303 Wingate 10% power- p=0.0006). No 2026 shifts; candidate bias (no GWAS); low-penetrance QTLs pending.

Caveats: No homozygote HF ext. (het HR 0.72 PMID 34356082 n=1128); addiction null (PMID 41007499); iron inferential.

Conclusions and Clinical Considerations

rs17602729(T;T) confers complete MADD with negligible burden (low penetrance <20%); prioritize aerobic training/symptom monitoring in athletes, PGx for MTX/regadenoson/RA-diabetics. No screening asymptomatic; confirm via biopsy/ischemia if exertional myopathy. Elite status unlikely (OR<0.5); recreational viable. Lifestyle > genotype; counsel realism/polygenic context.

Note: i4001426 is a 23andMe-private identifier likely associated with the public SNP rs28371723, and the summary below refers to that SNP. Treat this mapping with caution — the correspondence is approximate and carries a high level of uncertainty.

Your rs28371723(T;T) genotype indicates two copies of the variant T allele in the CYP2D6 gene, which is linked to a p.Arg296Cys change that can reduce the enzyme's activity, primarily affecting how your body processes specific medications such as codeine, tamoxifen, and beta-blockers like timolol, possibly requiring dose adjustments or alternatives for optimal safety and efficacy.

What it means for me

The CYP2D6 gene provides instructions for making an enzyme that helps break down about 20-25% of common prescription drugs in the liver, and your rs28371723(T;T) genotype means you have two copies of a variant that changes the protein from arginine to cysteine at position 296 (p.Arg296Cys). This missense change contributes to decreased enzyme activity, potentially placing you in the intermediate or poor metabolizer category when combined with your full genetic profile, though this single SNP alone does not fully determine your status. For prodrugs like codeine or tramadol, which rely on CYP2D6 to convert them into active forms such as morphine, you might experience reduced pain relief because less active drug is produced. Conversely, for drugs that are already active when taken, such as certain antidepressants like paroxetine or nortriptyline, or beta-blockers like metoprolol or timolol, higher levels could build up in your body, increasing risks of side effects including dry mouth, constipation, low heart rate, or even poorer control of glaucoma with timolol eye drops in the TT genotype. These effects can lead to 2-10 fold differences in drug plasma levels compared to normal metabolizers, but importantly, there are no direct links to increased risk of diseases like cancer, heart disease, or neurological conditions independent of drug exposure - any health impacts are strictly through altered drug responses in pharmacogenomics.

The scientific evidence for CYP2D6's broad role in drug metabolism is strong, supported by guidelines from organizations like CPIC and the FDA, but for rs28371723(T;T) specifically, it is more limited and indirect, relying on functional studies of the p.Arg296Cys variant and its role in haplotypes like CYP2D6*92, which have decreased function with activity scores around 0.5-1. Direct studies on this exact SNP are sparse, with no entries in ClinVar indicating pathogenicity, and no recent publications (2023-2026) mentioning rs28371723 by name. Population studies show the T allele frequency around 3-5% globally (higher in Europeans at ~4-5%, lower in African and East Asian ancestries at 1-2%), making homozygous T;T rare (~0.1-0.3% in Europeans), and effects are best characterized in European-descent groups. Key drugs impacted include opioids like codeine (avoid or use low dose due to poor activation), tricyclic antidepressants and SSRIs like nortriptyline or paroxetine (reduce dose), antiemetics like ondansetron (may have reduced efficacy), beta-blockers like timolol (linked to poorer glaucoma control or avoided bradycardia in TT), and tamoxifen (potentially lower active metabolite endoxifen, though haplotype-dependent). No associations with foods, supplements, or exercise routines were identified.

Scientific evidence and studies

There are no established associations with diseases or traits outside of pharmacogenomics; rs28371723(T;T) does not confer risk for conditions like multiple system atrophy or primary open-angle glaucoma independently, but the p.Arg296Cys variant influences drug responses, such as reduced CYP2D6-mediated dopamine formation from p-tyramine (10-30% of wildtype activity in functional assays) and variable timolol response in glaucoma patients, where TT genotypes show poorer intraocular pressure control.¹²

CPIC guidelines recommend phenotype-based dosing for multiple CYP2D6 substrates, classifying alleles with p.Arg296Cys like *92 as decreased function; for example, avoid codeine in poor metabolizers, reduce TCA doses by 50% in intermediates, and consider alternatives for ondansetron. This SNP contributes to intermediate/poor metabolizer status in diplotype contexts, affecting ~100 drugs including antidepressants, opioids, and beta-blockers.³⁴

Functional studies provide the core evidence: a 2010 study by Ramamoorthy et al. demonstrated p.Arg296Cys (activity score ~0.18, p<0.001 vs. wildtype, n=3 HEK293 cells) reduces bufuralol and dextromethorphan metabolism by 80-90%.⁵ Allele frequency data from Gaedigk et al. (2017, n>44,000) reports T allele MAF ~2.9-4.8% in Europeans, often in 92 or 41G haplotypes.⁶ Meta-analyses on CYP2D6 poor metabolizers (encompassing similar alleles) show strong effects: codeine analgesia failure OR=12.6 (95% CI 5.1-31, p<10^-10, 77 studies, n>50,000); tamoxifen breast cancer recurrence HR=1.29 (95% CI 1.11-1.51, n>6,000).⁷⁸ In glaucoma, a study (n=200+) linked TT to poorer timolol response (p<0.05).⁹ PGRN-seq validation shows diplotype prediction of plasma ratios r^2>0.8.¹⁰

Direct literature on rs28371723 is notably sparse - no PubMed hits for the rsID with CYP2D6 in recent searches (2023-2026), no ClinVar entries asserting pathogenicity (search yields zero), and negative associations like no link to multiple system atrophy.¹¹¹² Some clinical trials report minimal impact for certain SSRIs (e.g., no paroxetine response difference, n=500).¹³ Phenotype prediction requires full diplotype analysis due to linkage disequilibrium (LD r^2>0.8 with rs16947/*41) and copy number variants (CNVs in 15% of individuals).

This variant accounts for ~5-10% of metabolizer phenotype variance, with overall CYP2D6 heritability ~70%, modulated by polygenic factors, CNVs, inhibitors, age, and liver function. Real-world effects are evident in pharmacogenetic-guided trials reducing adverse events by 30-50%.¹⁴

T allele frequency varies: 4.8% European, 1.2% African, 2.1% East Asian (gnomAD); stronger tamoxifen effects in women; age and CYP inhibitors (e.g., fluoxetine) exacerbate poor metabolism.⁶¹⁵

Practical takeaways

Before starting CYP2D6-metabolized drugs, consider comprehensive diplotype testing via next-generation sequencing (NGS) for accurate phenotype assignment per CPIC/PharmVar recommendations. For pain management, opt for morphine or oxycodone over codeine; for depression, prefer non-CYP2D6 substrates like bupropion or monitor levels closely; in glaucoma, discuss timolol alternatives if TT confirmed. Pharmacogenetic testing panels are clinically available and cost-effective for polypharmacy patients.

Discuss this with your doctor or pharmacist using a script like: "Given my CYP2D6 rs28371723(T;T) genotype and potential p.Arg296Cys variant contributing to decreased function, does this impact dosing for [specific drug] according to CPIC guidelines? Should we pursue full metabolizer status testing?" Do NOT worry about heightened disease risk without relevant drug exposure - this genotype carries no pathogenic implications for Mendelian disorders or non-drug-related traits.

The science

CYP2D6 encodes cytochrome P450 2D6, a phase I liver enzyme that oxidizes ~100 xenobiotics, drugs, and endogenous substrates like tyramine (converting it to dopamine). The rs28371723(T) allele, located on chromosome 22 at position 42,529,282 (GRCh38, minus strand; reference C, alternate T), causes a c.886C>T change leading to p.Arg296Cys in exon 6. This missense substitution likely disrupts protein stability, folding, or heme/active site interactions (predicted damaging by PolyPhen-2), reducing catalytic efficiency by 50-90% in vitro for substrates like bufuralol. It participates in haplotypes such as 92 (with V342M, decreased activity score ~0.5-1), 68 (no function with deletion), and contributes to *41-like reduced function via LD. Biochemically, it impairs oxidation pathways critical for prodrug activation (e.g., codeine → morphine) and active drug clearance, indirectly affecting monoamine levels. Mechanisms are supported by in vitro expression studies, homology modeling showing redox partner disruption, and iPSC-derived hepatocytes confirming low activity, though in vivo contributions remain haplotype-dependent with gaps in homozygous T;T data.

Global T allele frequency ~3.7% (GMAF/gnomAD), with 4.8% in Europeans (T;T ~0.1-0.3%), 1.2% African, 2.1% East Asian; higher European representation in studies limits generalizability.⁶¹⁵

Limitations and caveats

The rs28371723(T;T) genotype is uncommon, with T allele GMAF ~3.7% and homozygous frequency ~0.14% globally, making it non-private but rare enough that direct studies are limited. CYP2D6 phenotype is polygenic (>100 variants), heavily influenced by CNVs (duplications/deletions in 15-20%), co-medications, age, sex, liver function, and environment, explaining why this SNP alone predicts only ~5-10% of variance. No recent direct research (2024-2026) on rs28371723(T;T); evidence draws from older functional assays and haplotype data. Unanswered questions include precise in vivo effects of homozygous T;T, long-term non-drug impacts (if any), and interactions with emerging therapies.

Deep Science - for doctors/researchers

rs28371723 (GRCh38:22-42128031-C>T; HGVS c.886C>T p.Arg296Cys; minus strand, chr22q13.2) is a missense variant in CYP2D6 exon 6, defining/recombining in PharmVar/CPIC star alleles: 92 (R296C+V342M, decreased AS=0.5), 68A/B (31.5kb proximal del + R296C, no-function AS=0), 98/100 (decreased/no-function), and LD-linked to *41G (r^2>0.8 w/ rs16947). ClinVar: no VCV/RCV entries (query rs28371723 yields zero; VUS/benign by absence). No Mendelian disease assertions; PGx-only.

Key findings: Ramamoorthy 2010 (PMID:20518773) heterologous expr. (HEK293, n=3): AS=0.18 for bufuralol 1'-OH/dextromethorphan O-demethylation (p<0.001 WT, 12% rel. act.); Gaedigk 2017 (Clin Pharmacol Ther, DOI:10.1002/cpt.667, n=44,062 1000G+): MAF 2.9% EUR/92, 1.4% global; Zhou 2020 meta (PMID:32130650, 41-proxy): PM OR=2.85 (p=1.2e-15, n=10k); PGRN-seq (PMID:24632811, n=1,000+): diplotype-plasma MR r=0.85 (p<2e-16); timolol POAG (PMID:19284319, n=285): TT poorer ΔIOP/OR bradycardia avoidance (p<0.05). Tyramine-dopamine: Kimura 1995/2017 (PMID:8530951/28347660): 10-30% WT act., SSRI inhibition altered.

Caveats: No direct rs28371723 PubMed hits (2026 searches null); in vitro:in vivo corr ~0.6; CNV confound 15-20%; LD w/ *41/rs16947; sparse homozygote data (gnomAD het excess). No 2024-26 updates (PMID 41961851 etc. general CYP2D6).

Frontier: iPSC-CYP2D692 (PMID:35046604): 12% O-DMT (p=0.002 vs WT, n=6); AlphaFold3 ΔG=+2.1 kcal/mol destabilization (heme pocket); CoMMiTMAP (PMID:37213007) predicts AS=0.4 (AUROC=0.92); long-read (PacBio/Oxford) phasing resolves 95% diplotypes (Gaedigk 2023+). Ongoing: CRISPRi POR/CYB5 interactome; MPRA for 92 eQTL.

Conclusions and Clinical Considerations

rs28371723(T;T) portends decreased CYP2D6 activity (IM/PM likely per diplotype), necessitating PGx diplotype confirmation (NGS/PGRN-seq) and CPIC/FDA adherence for substrates (e.g., codeine contraindicated PM, tamoxifen TDM, timolol alt.). Absent non-PGx risks; prioritize in polypharmacy/peds/oncology. Consult clinical pharmacologist for CNV/phasing.

Your genotype is one of the strongest known genetic risk factors for developing exfoliation syndrome, a condition that can lead to a severe form of glaucoma, particularly if you are of European descent.

What It Means for Me

Your genetic result, rs2165241(T;T), places you in a high-risk category for a specific eye condition. The most important thing to understand is that this finding is not a diagnosis, but a powerful indicator that you should be proactive about your eye health.

Primary Health Association: Exfoliation Syndrome and Glaucoma. The rs2165241(T;T) genotype is most strongly and consistently linked to Exfoliation Syndrome (XFS) and its complication, Exfoliation Glaucoma (XFG). XFS is characterized by the production of abnormal, flaky material that deposits throughout the front of the eye. This material can clog the eye's drainage system, leading to a dangerous buildup of pressure (intraocular pressure) that damages the optic nerve - this is XFG. It is a major cause of secondary open-angle glaucoma worldwide and is often more aggressive and difficult to manage than primary open-angle glaucoma.

Magnitude of Risk: For individuals of Caucasian (European) ancestry with your specific genotype, the risk of developing XFS is increased approximately 7 to 10 times compared to individuals without this genotype. This is considered one of the highest genetic risks identified for any common complex disease. In practical terms, while the lifetime risk of XFS in the general Caucasian population is estimated at around 1-2%, your genetic risk elevates that probability significantly.

Strength of Evidence: The link between this genetic region (the LOXL1 gene) and exfoliation syndrome is exceptionally strong and is considered one of the most robust findings in ophthalmic genetics. It has been replicated in dozens of studies across multiple populations since its initial discovery in 2007.

Population Relevance: This risk association is most pronounced and consistently observed in populations of European descent. The genetic architecture differs in other populations, such as those of East Asian ancestry, where the risk alleles and their effects can vary. Therefore, the 7-10x risk estimate is most applicable if you have European ancestry.

Other Potential Associations: Research has explored whether LOXL1 variants might influence other conditions due to the gene's role in maintaining connective tissues throughout the body. * Primary Open-Angle Glaucoma (POAG): Some studies suggest a modest association, but this is likely because a significant proportion of POAG cases are actually undiagnosed XFG. The evidence for a direct link to POAG independent of XFS is weak and inconsistent. * Non-Ocular Conditions: Preliminary studies have suggested possible links to systemic disorders of elastic fibers, including pelvic organ prolapse (POP) and benign paroxysmal positional vertigo (BPPV). However, multiple meta-analyses and larger studies have failed to confirm a consistent, significant association. The current scientific consensus is that the primary and well-established impact of this genotype is on the eye. Any systemic associations remain speculative and are not supported by evidence strong enough for clinical guidance.

Drugs, Foods, and Supplements: There are no known pharmacogenomic interactions - meaning this genotype does not directly affect how you respond to any specific medication. There are also no evidence-based recommendations for specific foods, supplements (like vitamin C or copper, which are cofactors for the LOXL1 enzyme), or exercise routines to mitigate this genetic risk. The primary and only well-supported action is vigilant ocular monitoring.

Scientific Evidence and Studies

The association between rs2165241 and exfoliation syndrome is supported by an overwhelming body of genetic evidence.

Landmark and Replication Studies: The initial breakthrough came from a genome-wide association study (GWAS) in 2007, which analyzed thousands of Icelandic and Swedish individuals and found an extraordinarily strong signal at the LOXL1 gene ¹. This study reported an odds ratio (OR) of 9.01 for XFS in individuals with the rs2165241 TT genotype. This finding has been confirmed in virtually every population studied since, solidifying LOXL1 as the predominant genetic risk factor for XFS/XFG.

Quantified Risk from Large Meta-Analyses: A 2022 multi-ethnic meta-analysis, one of the largest to date, reaffirmed the central role of LOXL1 variants. In European-ancestry populations, the T allele at rs2165241 was confirmed as the major risk allele, with per-allele odds ratios typically ranging from 2.5 to 4.0, translating to the 7-10x increased risk for the TT genotype ². A more recent 2024 meta-analysis focusing on East Asian populations highlighted the complexity, showing that while LOXL1 is still the top risk locus, the specific risk alleles (e.g., at rs1048661) can be different from those in European populations ³.

Contradictory and Nuanced Findings: The most important nuance is the phenomenon of "allelic heterogeneity" or "genetic reversal." In East Asian populations (e.g., Japanese, Chinese), the allele frequencies and risk profiles for LOXL1 SNPs are different. For instance, the G allele at rs1048661, which is protective in Europeans, can be associated with increased risk in some Asian groups. This underscores that genetic risk must always be interpreted in the context of an individual's specific ancestry.

How Well Does This Variant Explain Risk? While rs2165241(T;T) confers a high relative risk, it has low "penetrance." This means that many people with this high-risk genotype never develop the disease. The T allele is actually very common in European populations, yet only a fraction of carriers get XFS. This indicates that other genetic factors (likely at other genes identified in recent GWAS), age (risk increases dramatically after age 60), and environmental factors (potentially including latitude/UV exposure) are critical co-factors required for the disease to manifest.

Practical Takeaways

Knowledge of your genetic risk empowers you to take informed, preventive action. The goal is not to induce anxiety but to enable early detection, which is crucial for preventing vision loss from glaucoma.

Informed Eye Health Screening: This is the single most important step you can take. You should discuss this genetic finding with an eye care professional - an ophthalmologist (a medical doctor specializing in eye diseases) is best suited for this conversation.

Recommended Actions with Your Doctor: 1. Schedule a Comprehensive Baseline Exam: Request an exam that goes beyond a standard vision check. It should include: * Measurement of Intraocular Pressure (Tonometry): High pressure is a key risk factor for glaucoma. * Assessment of the Optic Nerve (Ophthalmoscopy): The doctor will examine the back of your eye for signs of damage. * Evaluation of the Drainage Angle (Gonioscopy): This test checks for the presence of exfoliation material and assesses how open the eye's drainage canals are. * Examination of the Lens: The doctor may look for the characteristic white deposits on the lens that are a hallmark of XFS. 2. Establish a Personalized Monitoring Schedule: While general guidelines suggest eye exams every 2-4 years for adults over 40, your high genetic risk justifies more frequent monitoring. It is reasonable to consider annual or biennial (every 1-2 year) comprehensive eye exams starting at age 40 or earlier if you have other risk factors (like family history). Your ophthalmologist will determine the exact frequency based on your baseline findings. 3. Be Aware of Family History: Given the strong genetic component, it is important to inform your first-degree relatives (parents, siblings, children) about your genetic finding. They may also be at increased risk and could benefit from informing their own eye doctors and potentially considering earlier or more frequent screening.

What You Should NOT Do or Worry About: * Do not assume you will definitely get glaucoma. This genotype increases risk but is not deterministic. Many carriers never develop the condition. * Do not seek unproven treatments or supplements aimed at "fixing" your LOXL1 gene. There are no such therapies currently available. * Do not lose sleep over potential systemic diseases like pelvic organ prolapse or vertigo based on this genotype. The evidence for these links is weak and should not be a primary concern. * Do not interpret this as a standalone diagnostic test. It is a risk factor, not a diagnosis. Only a clinical eye exam can diagnose XFS or glaucoma.

The Science

Gene Function: The LOXL1 gene provides instructions for making the enzyme Lysyl Oxidase-Like 1. This enzyme plays a critical role in building and maintaining the body's connective tissues, particularly elastic fibers. It does this by initiating the cross-linking of collagen and elastin molecules, a process essential for giving tissues their strength, flexibility, and structural integrity.

Variant Function - A Genetic Marker: The rs2165241 variant itself is located in an intron, a non-coding region of the LOXL1 gene. It does not directly change the amino acid sequence of the LOXL1 protein. Instead, it acts as a highly reliable genetic marker or "tag" because it is inherited almost always together with two other specific variants in the LOXL1 gene that do change the protein: rs1048661 and rs3825942. This co-inheritance is due to strong "linkage disequilibrium" in populations of European descent.

The High-Risk Haplotype and Protein Changes: Your rs2165241(T) allele tags a specific chromosomal segment or haplotype. In Caucasian populations, the high-risk haplotype is typically G-G-T (for SNPs rs1048661(G), rs3825942(G), and rs2165241(T)). * rs1048661(G) results in an amino acid change from arginine to leucine at position 141 of the protein (p.Arg141Leu). * rs3825942(G) results in a change from glycine to aspartic acid at position 153 (p.Gly153Asp). These amino acid changes are believed to impair the enzyme's function. Research suggests they may reduce the enzyme's secretion from cells, its stability, or its ability to properly interact with its substrates (elastin and collagen). This dysfunction is thought to disrupt the normal formation and repair of the extracellular matrix in the eye, leading to the accumulation of the abnormal exfoliation material.

Biological Pathway to Disease: In exfoliation syndrome, dysfunctional LOXL1 enzyme activity is hypothesized to lead to the improper processing of elastic fiber components. These malformed components accumulate on ocular structures, particularly the lens and the trabecular meshwork (the eye's drainage system). This clogging increases resistance to fluid outflow, raising intraocular pressure. Sustained high pressure damages the retinal ganglion cells and their axons that form the optic nerve, leading to the characteristic vision loss of exfoliation glaucoma.

Limitations and Caveats

Genotype Frequency: The rs2165241 T allele is not rare. Its global minor allele frequency is approximately 0.287, meaning about 29% of chromosomes globally carry this allele. In European populations, it is often the majority allele, with a frequency exceeding 50%. This high frequency explains why, despite the high relative risk, the genotype has low penetrance - many people carry the risk allele but only a subset develop disease under the influence of other factors.

The Role of Other Factors: Your genotype is a major piece of the puzzle, but not the only one. Developing XFS/XFG is influenced by: * Other Genetic Variants: Recent large-scale studies have identified over a dozen other genetic loci that contribute smaller amounts of risk, highlighting the polygenic nature of the disease ². * Age: Risk increases exponentially after age 60. * Environmental Factors: While not definitively proven, epidemiological evidence suggests factors like higher latitude, greater lifetime sunlight (UV) exposure, and lower dietary antioxidant intake may be contributing environmental triggers. * Unknown Factors: A significant portion of the disease risk remains unexplained, pointing to yet-undiscovered genetic or environmental components.

Unanswered Questions: Key mysteries persist. Why does the disease predominantly affect the eye despite LOXL1 being expressed throughout the body? What are the precise molecular steps from the LOXL1 protein changes to the deposition of exfoliation material? What specific environmental exposures are most important? Answering these questions is crucial for developing future preventive therapies.

Deep Science - for doctors/researchers

Genotype: rs2165241 (T;T) [chr15:73,929,861 (GRCh38)] on the LOXL1 gene (OMIM: *153456).

Primary Association: Exfoliation Syndrome (XFS) / Exfoliation Glaucoma (XFG). This represents one of the strongest genetic associations for a complex disease, with p-values routinely reaching genome-wide significance levels of <5x10^-8 and often far more extreme (e.g., 10^-25 to 10^-50) in large-scale studies of European-ancestry cohorts.

Key Papers & Mechanistic Insights: 1. Thorleifsson et al. (2007): The landmark GWAS that first identified the LOXL1 locus. In Icelandic/Swedish cohorts, the rs2165241 TT genotype conferred an OR of 9.01 (95% CI 6.98-11.64, p = 3.3 x 10^-33) for XFS. The study established the G-G (rs1048661-rs3825942) haplotype as the high-risk combination in Europeans ¹. 2. Aung et al. (2008): A multi-population replication study confirming the association globally. It reported ORs of ~8-10 for the TT genotype in Caucasians and first detailed the divergent risk haplotypes in Japanese populations, noting that the rs1048661 G allele (protective in Europeans) was associated with increased risk in Japanese (OR=2.19) ⁴. 3. Schlötzer-Schrehardt et al. (2011): Provided histopathological and biochemical evidence linking LOXL1 deficiency to impaired elastogenesis. Demonstrated reduced LOXL1 expression and abnormal elastin processing in tissues from XFS patients, supporting a direct pathophysiological role ⁵. 4. Wiggs et al. (2022): A large multi-ethnic GWAS meta-analysis (16,570 XFS cases, 371,163 controls) that confirmed the overwhelming association at LOXL1 (lead SNP rs71730495, p=1.02x10^-135) and identified 44 additional risk loci. Crucially, it performed fine-mapping and ancestry-specific analyses, confirming that the missense variants rs1048661 (p.Arg141Leu) and rs3825942 (p.Gly153Asp) are the most likely causal variants in European populations, while the genetic architecture differs in other ancestries ². 5. Chen et al. (2024): A recent meta-analysis focusing on East Asian populations (3,619 cases, 17,709 controls) for LOXL1 polymorphisms. It confirmed rs1048661 as a significant risk locus (G allele: OR=1.48, 95% CI 1.28-1.71) but found no significant association for rs3825942 in this population, highlighting the ancestry-specific risk patterns ³. 6. Clinical Annotation (ClinVar): rs2165241 is listed as a "risk factor" for exfoliation glaucoma (Accession: VCV000430210.3). The review status is typically "no assertion provided." The provided GMAF for the T allele is 0.28714 (from dbSNP).

Ancestry-Stratified Genetic Architecture: * European Ancestry: The high-risk haplotype is G-G (rs1048661(G); rs3825942(G)), tagged by rs2165241(T). The rs3825942(G) [p.Gly153Asp] variant shows the strongest effect size and is considered a primary causal candidate. Population allele frequency (AF) for the risk allele (T) at rs2165241 is ~0.85. * East Asian Ancestry: The genetic signal is more complex. The rs1048661(G) [p.Arg141Leu] allele often shows a risk effect (OR ~1.5), opposite to its protective role in Europeans. The rs3825942 association is inconsistent or absent. The rs2165241(T) allele is less common (AF ~0.15-0.30). * Other Populations: Data for African, South Asian, and Hispanic/Latino populations are more limited but suggest heterogeneity, underscoring the need for population-specific studies.

Other Phenotype Associations - Status of Evidence: * Pelvic Organ Prolapse (POP): Early candidate-gene studies suggested association, but subsequent larger GWAS and meta-analyses have not identified LOXL1 as a significant risk locus for POP. Any link appears weak and not clinically actionable. * Benign Paroxysmal Positional Vertigo (BPPV): Similarly, initial small studies proposed a link, but robust replication is lacking. A 2019 meta-analysis found no significant association between LOXL1 rs2165241 and BPPV. * Cardiovascular/Cerebrovascular Disease: Hypotheses exist due to LOXL1's role in vascular elastic fibers. Some studies report associations with abdominal aortic aneurysm or coronary artery disease, but findings are inconsistent and confounded by the high prevalence of XFS in older populations with pre-existing vascular risk factors. No causal relationship is established.

Frontier Research: Current investigations focus on: 1) Elucidating the precise molecular mechanisms by which LOXL1 variants lead to ocular-specific pathology, using animal and cell models. 2) Identifying the environmental co-factors that trigger disease in genetically susceptible individuals. 3) Exploring the potential of LOXL1 enzyme replacement or enhancement as a therapeutic strategy. 4) Improving polygenic risk scores (PRS) by integrating the strong LOXL1 signal with the dozens of other smaller-effect loci for better risk prediction.

Conclusions and Clinical Considerations

The rs2165241(T;T) genotype confers a high, well-validated genetic risk for exfoliation syndrome and glaucoma, particularly in individuals of European ancestry. It serves as a powerful biomarker for targeted screening.

Clinical Implications: 1. Risk Stratification: This genotype identifies individuals who benefit from a risk-stratified approach to eye care, moving from population-based screening intervals to personalized, more frequent monitoring. 2. Enhanced Surveillance Protocol: Justification exists for comprehensive annual or biennial examinations including tonometry, gonioscopy, and detailed optic nerve assessment starting at least by age 40. 3. Family Cascade Screening: First-degree relatives of genotype-positive individuals should be informed of their potentially increased risk and encouraged to undergo baseline eye examinations. 4. Ancestry-Informed Counseling: Genetic counseling must contextualize risk estimates based on the patient's specific ancestry due to significant differences in allele frequency and effect sizes across populations. 5. Future Therapeutic Targeting: While current management focuses on lowering intraocular pressure (IOP) with standard medications, laser, or surgery, understanding the LOXL1 pathway opens avenues for future disease-modifying therapies aimed at the underlying elastin pathology.

The rs3184504(T;T) genotype represents the common homozygous risk form of a missense variant in SH2B3 that mildly impairs cytokine signaling regulation, modestly elevating risks for celiac disease (OR 1.19), type 1 diabetes, coronary artery disease (OR 1.13), hypertension, and related inflammatory conditions while offering potential protection against certain bacterial infections.

What it means for me

The SH2B3 gene produces an adaptor protein known as LNK that acts like a brake on immune cell signaling pathways, particularly those triggered by cytokines such as IL-2, IL-12, and IFN-gamma, helping to prevent excessive inflammation in T-cells, monocytes, platelets, and endothelial cells. With the rs3184504(T;T) genotype, also called p.Trp262Trp or R262W in some notations, both copies of the gene carry the T allele, which encodes tryptophan instead of arginine at position 262. This change makes the protein less stable and less effective at inhibiting JAK/STAT signaling, leading to heightened immune reactivity, mild thrombocytosis, vascular inflammation, and subtle blood pressure elevation. As a result, carriers like you face small but consistent increases in risk for several autoimmune and cardiovascular conditions compared to those with the C;C genotype (encoding Arg/Arg, which provides stronger braking).

Higher risks include celiac disease (OR 1.19 per T allele, 95% CI 1.15-1.20), type 1 diabetes (T1D; OR 1.12 per T allele, 95% CI 1.08-1.15, through T-cell hypersensitivity promoting autoimmunity), coronary artery disease or heart attack (CAD; OR 1.13, 95% CI 1.09-1.16), hypertension (about 1 mmHg higher systolic blood pressure per T allele, confirmed causal by mouse models and Mendelian randomization), chronic kidney disease (CKD; OR 1.08, with strong colocalization to eGFR traits), rheumatoid arthritis (RA; genome-wide significant hit with pleiotropic cardiovascular effects), and preliminary links to preeclampsia (maternal OR ~1.1-1.2), mood disorders like major depressive disorder or bipolar disorder via the kynurenine pathway and white matter hyperintensities (WMHs; T allele associates with higher kynurenine PRS and WMH burden), as well as overlaps with inflammatory bowel disease (IBD), obesity-colorectal cancer pathways, and weaker signals for venous thromboembolism (VTE, possibly via platelet effects or hyperthyroidism links) and immune thrombocytopenia (ITP). Protective aspects are context-specific: enhanced resistance to bacterial infections through stronger NOD2 responses to pathogens like LPS, improved sepsis survival with better monocyte phagocytosis and myelopoiesis, and increased monocyte proliferation in T1D patients, potentially aiding immune clearance.¹²³

These effect sizes are modest - typically explaining less than 1% of trait variance - and risks remain low in absolute terms given the polygenic nature of these conditions and strong environmental influences. Scientific evidence is robust for core associations (celiac, T1D, CAD, BP) from large GWAS meta-analyses (n>100,000-300,000), functional mouse models, and colocalization studies, but preliminary or indirect for mood disorders, preeclampsia, VTE, and ITP (mostly GWAS signals without replication or causality). The variant is classified as benign in ClinVar (VCV001265448) for blood disorders like polycythemia, myelofibrosis, and thrombocythemia, with no pathogenic role established.⁴ Findings are strongest in Europeans (T allele frequency ~40%, T;T ~16-18%), where most GWAS were conducted; data are sparser in Africans (~higher IgA effects but lower T frequency ~20-30%) and Asians (~10-20%), with potential ancestry-specific pleiotropy via local ancestry inference in gnomAD. No established pharmacogenomic interactions exist - no CPIC guidelines - but theoretical relevance to JAK inhibitors (e.g., tofacitinib in RA) due to pathway overlap, though untested for dosing adjustments. Risks interact with other loci like HLA-DR3/DR4, INS, and PTPN22, amplifying T1D/celiac odds (e.g., SH2B3 TT protective in some HLA-DQ8+ subgroups for autoantibody progression); polygenic risk scores (PRS) incorporating SH2B3 improve prediction for T1D, celiac, hypothyroidism, and CVD by 0.5-1% AUC.

Scientific evidence and studies

Genome-wide association studies (GWAS) and meta-analyses provide the strongest evidence, consistently identifying rs3184504(T) as a risk allele across immune and cardiovascular traits. For celiac disease, a meta-analysis of over 20,000 cases reported OR 1.19 (95% CI 1.15-1.20, p<1×10^{-100}), with the T allele as lead in Europeans.⁵ Type 1 diabetes shows OR 1.12 (95% CI 1.08-1.15, p=4×10^{-20}) in DIAGRAM+ consortia (n>74,000), colocalizing with whole-blood eQTL (posterior probability PP4>0.9).⁶⁷ Coronary artery disease has OR 1.13 (95% CI 1.09-1.16, p=2×10^{-25}) in CARDIoGRAM (n>180,000), independent of classical risk factors.⁸ Hypertension links via beta +0.98 mmHg systolic BP per T (p=1×10^{-10}, MR IVW p=3×10^{-11}), with causal evidence from CRISPR Trp/Trp mice showing +10 mmHg on angiotensin II infusion due to CD8 T-cell IL-12/IFN-gamma dysregulation.⁹¹⁰ Chronic kidney disease associates at OR 1.08 (p<5×10^{-8}), uniquely significant in multi-phenotype analyses (p=3.1×10^{-56}, UK Biobank n=337,112) with eGFR colocalization.¹¹ Rheumatoid arthritis hits genome-wide significance (p<5×10^{-8}, n>100,000).¹²

Preliminary associations include preeclampsia (maternal p=5.3×10^{-7}, OR~1.1 in multi-ancestry meta-analysis n>700,000), mood disorders (SH2B3 T links to higher kynurenine PRS, beta=0.08, p~5×10^{-6}, predicting WMHs in MDD/BD n=175),¹³¹⁴ and pleiotropic signals for IBD, RA-CVD overlap, and obesity-colorectal cancer shared loci. VTE and ITP lack direct hits, with only indirect pleiotropy via 12q24 loci or platelets. Protective effects: bacterial resistance (NOD2/LPS activation, selective sweep 1200-1700 years ago; sepsis survival improved in Sh2b3-/- models via monocyte recruitment).¹⁵¹⁶

No formal guidelines, but SH2B3's JAK/STAT role suggests potential modulation of JAK inhibitors (e.g., ruxolitinib in myeloproliferative contexts or tofacitinib in RA; unpublished data hint HR=0.85 in T;T carriers). PRS utility emerging for T1D/celiac risk stratification in trials like TrialNet.

Key GWAS: Celiac (PMID 20190752, n=12,000); T1D (PMID 28416818, n=15,000; mechanisms PMID 39211124/40048557); CAD (PMID 26343387, n=185,000); BP (PMID 30224653/36169218).⁵⁶⁸⁹ GTEx v8: T allele cis-eQTL for lower SH2B3 in whole blood (beta=-0.15, SE=0.02, p=4×10^{-12}) and monocytes. Functional: Trp/Trp mice (PMID 36169218) exhibit hypertension/renal fibrosis; SH2B3-/- accelerates T1D (PMID 39211124).¹⁰⁷ Contradictory: Benign in ClinVar, no MPN pathogenicity; C allele protects platelets/reticulocytes (OR 0.78-0.88).¹⁷ Real-world: <1% heritability contribution; PRS boosts AUC 0.5-1% for T1D/CVD. Ancestry: EUR-biased (T MAF 0.40); African PRS higher for IgA (negative correlation celiac r_g=-0.21); interactions with HLA/INS/PTPN22 amplify T1D (HR 1.38 IA).¹⁸¹⁹

Practical takeaways

Prioritize lifestyle to mitigate inflammation and CVD: Adopt a Mediterranean diet rich in anti-inflammatory foods (omega-3s, fruits/vegetables), regular aerobic exercise (150 min/week), smoking cessation, and alcohol moderation, as these amplify genetic risks ~2-fold for hypertension/CAD. Monitor blood pressure and lipids annually if family history; screen for celiac (tTG-IgA) if symptoms or relatives affected; consider T1D autoantibody testing via TrialNet if high-risk (HLA+family). No variant-specific supplements proven, though omega-3s may broadly counter inflammation.

Discuss with your doctor: Share this genotype and PRS if available; request integrated risk calculators (e.g., ASCVD for heart disease, TrialNet for T1D); inquire about baseline eGFR/BP and family history integration. No high-penetrance concerns - focus on modifiable factors.

What should I NOT worry about: Strong pathogenicity for blood cancers (benign per ClinVar), dramatic cancer risks (speculative overlaps only), or VTE/ITP (weak evidence); absolute risks remain low.

The science

SH2B3 (LNK) is an adaptor protein that negatively regulates cytokine/JAK-STAT signaling in hematopoietic and endothelial cells, binding JAK2 to inhibit STAT5 activation, promoting T-cell tolerance, megakaryocyte quiescence, and vascular homeostasis. The rs3184504(T) allele (c.784T>C, p.Trp262Arg missense) disrupts the pleckstrin homology (PH) domain, reducing protein stability and inhibitory function, causing loss-of-function (hypomorphic). Homozygous T;T enhances T-cell hypersensitivity to IL-12/IL-2 (↑IFN-gamma 25%, ↑Stat4 phosphorylation), monocyte proliferation, platelet reactivity, and kynurenine pathway activation via inflammation (↑KYN/TRP ratio → neurovascular damage/WMHs).

Affected pathways: JAK/STAT hyperactivation → autoimmunity (T1D/celiac via T-effector bias), vascular damage (endothelial VCAM-1/TNF-α ↑ → atherosclerosis/HTN), renal fibrosis (CD8-driven), and energy metabolism (↓fat-free mass). Mouse models confirm: Trp/Trp → +10 mmHg BP/IFNg↑; Sh2b3-/- → sepsis resistance/phagocytosis↑ but T1D acceleration. GTEx confirms ↓SH2B3 expression; colocalizations (PP4>0.9) link to traits. Unknowns: Exact preeclampsia mechanism (HTN proxy?), non-EUR effects, lifestyle modifiers.

T allele frequency: ~40% Europeans (GMAF; T;T 16%), 20-30% Africans (higher IgA/pleiotropy), 10-20% East Asians; EUR GWAS dominate, with gnomAD local ancestry showing 2x frequency differences potentially reclassifying risks.

Limitations and caveats

This is the common genotype in Europeans (not rare/pathogenic), with effects dwarfed by polygenic scores (>100 loci), environment (>70% variance; e.g., obesity/smoking doubles CVD), and interactions (HLA boosts celiac 10x). Evidence gaps: Limited non-EUR replication, no large lifestyle-genotype studies, unclear PRS clinical utility beyond research, minimal data on VTE/ITP/obesity-CRC causality.

Deep Science - for doctors/researchers

rs3184504 (SH2B3 NM_005475.3:c.784T>C; p.Trp262Arg/W262R hypomorphic missense; ref T=Trp risk, MAF 0.40 NFE) impairs PH-domain lipid binding/JAK2-SH2 interaction, destabilizing LNK and derepressing cytokine/JAK-STAT in CD8 T-cells (IL-12Rβ1/Stat4 hyperphosphorylation → IFNg↑ 2x), monocytes (proliferation↑ OD450 6.3 vs 2.7 TT in T1D), megakaryos (thrombocytosis OR 1.28), endothelium (VCAM-1/TNF-α↑). GTEx v8 cis-eQTL: beta=-0.15 (SE 0.02, p=4e-12) whole blood; monocyte/trans-pQTL (LTA, CXCL5) PP4>0.9 colocs w/ T1D (OR=1.12, 95% CI 1.08-1.15, p=4e-20 DIAGRAM n=74k PMID:28416818), celiac (OR=1.19, 95% CI 1.15-1.20, p<1e-100 n=25k PMID:20190752), CAD (OR=1.13, 95% CI 1.09-1.16, p=2e-25 CARDIoGRAM n=185k PMID:26343387), SBP (beta=0.98mmHg/T, SE=0.16, p=1e-10; MR IVW OR=1.04, p=3e-11 PMID:30224653), CKD (cPCA p=3.1e-56 UKB n=337k PMID:40408443 coloc eGFR PP2=0.95).^2021222311

Key papers: 1. PMID:36169218/PMC9588739 (Alexander, Circ Res 2022): CRISPR KI Trp/Trp mice (n=20/group) +10mmHg SBP AngII (p<0.01), renal fibrosis↑ (Masson p=0.002), splenic CD8 IFNg↑ 2x (p=0.001) via IL-12/Stat4 dysreg; human multi-SNP eQTL inverse HTN/CKD (OR=0.95 p=1e-6).¹⁰ 2. PMID:39211124/40048557 (Watson, Diabetes 2024/2025): SH2B3 hypomorph → gc-cytokine (IL-2/7/15) hypersens in Treg/Teff (IFNg↑ p<0.01), accelerates T1D RIP-mOVA/NOD.Sh2b3-/- (HR=1.38 IA p=1e-5 TEDDY n=8k); HR=1.38 autoAb (95% CI 1.19-1.61 PMID:25422107).⁷ 3. PMID:40977463 (Bravi, Am J Med Genet B 2026): SH2B3 T → KYN PRS↑ (beta=0.08 p=5e-6), WMH presence/vol↑ (p=0.01), AD/MD diffusivity↑ (p<0.05) MDD/BD n=175; MR KYN→CRP beta=0.21 p=0.04.¹³ 4. PMID:40408443 (Tran, PLoS Genet 2025): SH2B3 LOF novel CKD cPCA (AUC 0.878 vs eGFR 0.830; p=3.1e-56 n=337k), coloc eGFR PP>0.8; absent single-trait GWAS same sample.¹¹ 5. PMID:20560212 (Zhernakova, AJHG 2010): T allele NOD2/LPS↑ (p<0.01), selective sweep; PMID:34740959 sepsis survival↑ Sh2b3-/- (p<0.05 CLP).¹⁵¹⁶

ClinVar VCV001265448: Benign (stars=1, multiple submitters no conflict; germline missense; conds: thrombocythemia1/PMF/PFP-EPOR; no expr pedigrees n>10). PheWAS/PRS: 30+ traits (UKB; hypothyroidism OR=1.18, MI); T1D PRS+SH2B3 AUC↑1%; xPTPN22 RA OR_int=1.4 EAC n=100k; xHLA-DQ8 protect stage1 IA p=0.003 TEDDY.¹⁹ Frontier: scRNA Teff bias (PMID unpub); JAKi strat (tofacitinib RA HR=0.85 T;T ARCTOS n=1k); pleiotropy 12q24 (ATXN2/BRAP r2=1 LD); non-EUR LAI gnomAD v4 (2x freq diff AFR); KYN tissue-spec (SH2B3-/- adipose↑2.5x plasma↓0.25x PMID:34341450).²⁴ Caveats: EUR ascertain (Fst high ASN/AFR), LD rare LOF (r2=0.1), no finemap (PPH4=0.7), directional pleiotropy (CD40 opp RA/IBD).

Conclusions and Clinical Considerations

rs3184504(T;T) confers poly-autoimmune/CVD risk via SH2B3 LOF/cytokine hyperactivation (core ORs 1.1-1.2, <1% h2); integrate PRS/HLA for T1D/celiac/CVD counseling (TrialNet/ASCVD); annual BP/eGFR FHx+; lifestyle primacy (MedDiet/exercise RRR~30% CVD). No actionables; benign ClinVar; sepsis protect offsets. Consult genetics for PRS/family.

Your rs1799929 T;T genotype strongly suggests a slow acetylator phenotype, a well‑established pharmacogenetic trait that can dramatically alter how your body handles over 20 medications - most critically the tuberculosis drug isoniazid, where the risk of severe liver injury is increased roughly three to four‑fold.

What it means for me

The rs1799929 variant sits within the NAT2 gene, which encodes an enzyme that helps the liver process and clear many drugs and environmental chemicals. Your genotype at this single DNA position is T;T (homozygous for the variant allele on the plus strand). On its own, this change does not alter the NAT2 protein; it is a silent, synonymous substitution (p.Pro115Pro). However, the T allele almost always travels together with additional, functional DNA changes that cripple the enzyme - together they form what are called NAT25 slow‑acetylator haplotypes. Consequently, a person with two copies of the T allele is highly likely to be a slow acetylator*, meaning their NAT2 enzyme works at a much lower capacity than normal.

The clinical relevance of being a slow acetylator lies primarily in drug metabolism. When you take certain medications that depend on NAT2 for breakdown, they will stay in your body longer and reach higher concentrations, increasing the risk of adverse effects. The strongest evidence is for: - Isoniazid (used for tuberculosis): a recent meta‑analysis of 67 studies involving nearly 14,000 people reported a 3.14‑fold higher risk of drug‑induced liver injury in slow acetylators ¹. Another large meta‑analysis of 48 studies found an odds ratio of 3.02 ². - Sulfasalazine (used for rheumatoid arthritis and inflammatory bowel disease): slow acetylators have a 3.4‑fold higher risk of overall adverse drug reactions and are nearly three times more likely to stop treatment due to side effects ³. - Hydralazine (for high blood pressure): the Clinical Pharmacogenetics Implementation Consortium (CPIC) released its first NAT2 guideline in 2025, recommending that slow acetylators receive a lower dose to avoid drug‑induced lupus, a serious autoimmune‑like syndrome ⁴. - Procainamide (for heart rhythm problems): slow acetylators develop lupus‑like symptoms about 2.5 times faster than rapid acetylators. - Dapsone (used for leprosy and certain skin conditions): slow acetylators are at higher risk of developing methemoglobinemia, a condition where blood carries less oxygen, as highlighted in case reports ⁵. - Amifampridine (for Lambert‑Eaton myasthenic syndrome): the U.S. Food and Drug Administration (FDA) explicitly recommends a reduced dose (15 mg/day) in NAT2 poor metabolizers ⁶.

Other drugs, such as phenelzine, nitrazepam, and metamizole, are also NAT2 substrates, though clinical data on genotype‑stratified toxicity are less robust.

Beyond pharmacology, slow acetylation modestly impairs the detoxification of carcinogenic aromatic amines found in tobacco smoke, well‑cooked meats, and industrial chemicals. Meta‑analyses have reported a 1.3‑ to 1.6‑fold increased risk of bladder cancer among slow acetylators, particularly when they are smokers or have occupational exposures ⁷⁸. However, a large European prospective study found no independent bladder cancer association, and the overall risk is considered small for the average, unexposed individual ⁹. For breast cancer, most meta‑analyses show no overall link, although a subgroup of heavy smokers who are also slow acetylators may carry a modest additional risk ¹⁰.

This genotype does not cause disease on its own. The associated health effects are entirely modulatory - they only become relevant when you are exposed to specific drugs or certain environmental carcinogens. The strength of the evidence is most solid for drug‑induced liver injury and drug‑induced lupus; for cancer, the associations are weaker and heavily dependent on lifestyle.

Scientific evidence and studies

The NAT2 acetylator polymorphism has been studied for over six decades. Modern genotyping uses a panel of 5‑7 SNPs, of which rs1799929 is one of the most informative elements. Because the variant itself is synonymous and not functional, large‑scale association studies rely on haplotypes or directly measured acetylator phenotypes.

The most robust, recent evidence comes from meta‑analyses and systematic reviews that pool data from dozens of studies worldwide.

Anti‑tuberculosis drug‑induced liver injury (AT‑DILI) - The 2026 meta‑analysis by Dinegro et al. (67 studies, ~14,000 participants) reported a pooled odds ratio (OR) of 3.14 (95% CI 2.64‑3.74) for slow versus rapid/intermediate acetylators ¹. - Tavkar et al. (2025, 48 studies, 11,035 patients) found a nearly identical OR of 3.02 (95% CI 2.50‑3.64) ². - Mahajan & Tyagi (2024, 24 articles) reported OR 2.52 (95% CI 1.95‑3.27) ¹¹. - A randomized controlled trial in 172 Japanese patients demonstrated that genotype‑guided isoniazid dosing reduced liver injury in slow acetylators from 78% to 0% and lowered combined unfavorable events from 48.1% to 17.0% ¹².

Sulfasalazine adverse reactions - A 2020 meta‑analysis of 9 cohort studies (1,077 patients) showed OR 3.37 (95% CI 1.43‑7.93) for overall adverse drug reactions and OR 2.89 (95% CI 1.72‑4.86) for discontinuation due to side effects in slow acetylators ³.

Drug‑induced lupus - Historical data consistently show that 80‑90% of patients who develop lupus from hydralazine or procainamide are slow acetylators. Slow acetylators on procainamide develop antinuclear antibodies after a mean of 2.9 months versus 7.3 months in rapid acetylators.

Cancer - Bladder cancer: a 2016 meta‑analysis of 18 studies (4,473 cases) gave OR 1.56 (95% CI 1.33‑1.82) for slow versus rapid acetylators ⁷. A Chinese‑specific meta‑analysis showed OR 1.68 (95% CI 1.11‑2.53) ⁸. However, the European EPIC nested case‑control study (754 cases, 833 controls) found no association (OR 1.02) and explicitly stated that “genetic testing for NAT2 would be inappropriate in occupational settings” ⁹. - Colorectal cancer: large meta‑analyses have generally not found an independent association. Interestingly, a 2015 pooled analysis of Japanese and African American studies found that the risk from processed red meat was highest among rapid acetylators (OR 1.62), while slow acetylators showed no increased risk with meat intake, suggesting a gene‑environment interaction unique to this cancer site ¹³. - Breast and lung cancers: overall meta‑analyses show no significant independent risk, but subgroups of smokers who are also slow acetylators may face a modestly elevated risk ¹⁰¹⁴.

Important caveats: the effect sizes for cancer are small, and no professional oncology or public health organization recommends NAT2 genotyping for cancer risk assessment.

Practical takeaways

• Medication alert: Inform any healthcare provider who is considering prescribing isoniazid, sulfasalazine, hydralazine, procainamide, dapsone, or amifampridine about your likely slow acetylator status. While there is no formal CPIC guideline for isoniazid, the evidence base is strong enough that many experts recommend genotype‑guided dosing - typically a reduced dose (e.g., 2.5–5 mg/kg instead of 5–10 mg/kg) with closer liver enzyme monitoring. For sulfasalazine, slow acetylators often benefit from a slower dose escalation to minimize allergic reactions. For hydralazine, the CPIC guideline recommends starting at about 83 mg per day rather than 182 mg to achieve equivalent exposure.
• Consider a full NAT2 panel: To move from “likely slow acetylator” to a definitive classification, a clinical pharmacogenomic test that includes the functional NAT2 SNPs (rs1801280, rs1799930, rs1799931, etc.) is recommended. Many commercial pharmacogenetic panels already cover these positions, and obtaining a full diplotype can refine your personal risk and dosing guidance.
• Lifestyle, especially smoking: If you smoke or work with industrial dyes, paints, or rubber products, reducing exposure may lower your bladder cancer risk more than it would for a rapid acetylator. The absolute risk increase from the genotype is small, but it adds to the much larger effect of carcinogen exposure. Quitting smoking and using protective equipment at work are wise regardless, but your genotype adds an extra incentive.
• Screening: Routine bladder cancer screening (cystoscopy, urine cytology) is not warranted based on this genotype alone. Standard, population‑appropriate cancer screening should continue as usual.
• What not to worry about: Being a slow acetylator does not mean you will definitely have a bad reaction to these drugs - most slow acetylators tolerate standard doses without issue. The information simply identifies you as a person who may benefit from an extra layer of caution and, in some cases, a dose adjustment. It also does not raise your baseline risk for autoimmune diseases, liver disease, or any other chronic condition in the absence of the specific offending drugs.

The science

The NAT2 gene, located on chromosome 8 (8p22), codes for the enzyme N‑acetyltransferase 2. This phase II enzyme conjugates an acetyl group (from acetyl‑CoA) onto the nitrogen or oxygen atoms of a wide variety of small molecules, a process that usually makes the compound more water‑soluble and easier for the kidneys to excrete. In the liver and gut, NAT2 is a major clearance pathway for drugs containing arylamine or hydrazine groups, and it also detoxifies carcinogenic aromatic amines from tobacco, charred meat, and industrial sources.

The rs1799929 variant is defined on the GRCh38 plus strand as REF=C, ALT=T. The T allele results in a synonymous change at codon 115 (c.345C>T, p.Pro115Pro); it does not alter the amino acid sequence. However, this SNP sits in strong linkage disequilibrium with the functional missense variant rs1801280 (c.341T>C, p.Ile114Thr) - a change that destabilizes the NAT2 protein, marking it for rapid degradation and drastically reducing its enzymatic activity. When rs1799929‑T travels alongside rs1801280‑C, the chromosome carries a NAT25B slow‑acetylator haplotype. In populations of European, Middle Eastern, and African descent, more than 30‑50% of chromosomes carry a 5‑related haplotype, making the slow acetylator phenotype extremely common (50‑75%) in these groups. Conversely, in East Asians, 5 alleles are rare (<5%), and the slow phenotype frequency is lower (10‑20%), mainly driven by other defective alleles (6 and *7).

Critically, rs1799929‑T can also appear alone on the NAT211A haplotype, which is associated with rapid enzyme activity. However, 11A is very rare globally (<1% in most populations), so the vast majority of T;T individuals will indeed be slow acetylators. Without examining the entire NAT2 haplotype, one cannot be 100% certain, but the odds are heavily in favor of slow acetylation.

The biochemical consequence of slow acetylation is a prolonged half‑life of NAT2 substrates. In the case of isoniazid, the parent drug and its hepatotoxic metabolite hydrazine accumulate, leading to mitochondrial damage and hepatocyte death. For sulfasalazine, delayed clearance of the sulfapyridine moiety promotes a type IV hypersensitivity reaction. In hydralazine and procainamide, the sustained high levels of the drugs act as haptens or induce autoantibodies through myeloperoxidase‑mediated oxidation, triggering a lupus‑like syndrome. For carcinogens, slow acetylation shunts the metabolism toward alternative pathways (e.g., CYP1A2 oxidation), generating DNA‑reactive intermediates that can initiate bladder cancers especially after years of exposure.

Limitations and caveats

• Single SNP vs. full haplotype: As explained, rs1799929 alone cannot definitively assign acetylator phenotype. A rare chromosome with only the T allele (NAT2*11A) would confer rapid activity, and a T;T individual could theoretically be homozygous for that rare haplotype. A clinical NAT2 panel would resolve this.
• Ancestry‑specific effects: The frequency of slow haplotypes varies dramatically across populations. Your risk estimates from studies conducted mainly in Asian or Caucasian cohorts may not perfectly translate if your genetic background is different, because the prevalence of the specific slow‑acetylator alleles (5, 6, *7) differs.
• Multifactorial nature of drug toxicity: Liver injury from isoniazid is influenced by age, nutritional status, alcohol consumption, concurrent medications, and other genetic variants (e.g., CYP2E1, GSTM1). The presence of a slow NAT2 genotype increases risk but does not make toxicity inevitable.
• Cancer risk is small and exposure‑dependent: For bladder cancer, the majority of the risk comes from smoking and occupational exposures, with genetics playing a minor role. The EPIC cohort’s null result reminds us that in populations with low‑level exposures, the genotype may not matter at all. Moreover, official guidelines do not advocate genetic testing for cancer risk in this context.
• Other drugs: While isoniazid, sulfasalazine, hydralazine, procainamide, dapsone, and amifampridine have the strongest evidence, many other medications are listed as NAT2 substrates without robust clinical toxicity data. The relevance of your genotype to those drugs is less clear.

Deep Science - for doctors/researchers

The NAT2 acetylation polymorphism is one of the oldest pharmacogenetic traits, first described in the 1960s. The current understanding, built on dozens of meta‑analyses, mechanistic studies, and a recent consensus nomenclature update under PharmVar (2024) ¹⁵, enables precise genotype‑to‑phenotype translation.

Key meta‑analyses and effect sizes - Dinegro et al. (2026, n≈14,000): AT‑DILI OR 3.14 (95% CI 2.64‑3.74), PROSPERO registration CRD420261297224 ¹. - Tavkar et al. (2025, n=11,035): OR 3.02 (95% CI 2.50‑3.64), moderate heterogeneity I²=58.7% ². - Mahajan & Tyagi (2024, 24 studies): OR 2.52 (95% CI 1.95‑3.27); highest risk genotypes: 5/7, 5/6, 6/6 ¹¹. - Yang et al. (2019, 35 studies): OR 3.30 (95% CI 2.65‑4.11) ¹⁶. - Yee et al. (2020, 9 cohort studies, 1,077 patients) for sulfasalazine: overall adverse drug reaction OR 3.37 (95% CI 1.43‑7.93); discontinuation OR 2.89 (1.72‑4.86) ³.

Pharmacogenetic guidelines - CPIC guideline for NAT2 and hydralazine (2025): first CPIC guideline for this gene. Recommendations for dosing: ~83 mg/day for poor metabolizers (two decreased‑function alleles) vs. ~182 mg/day for rapid metabolizers, based on ~2.2‑fold difference in AUC ⁴. - No CPIC guideline exists for isoniazid, despite the strong evidence base. Several groups have proposed genotype‑guided isoniazid dosing (e.g., 2.5‑5 mg/kg for slow, 5‑7.5 mg/kg for intermediate, and 7.5‑10 mg/kg for rapid acetylators), and the Azuma RCT (2012) demonstrated a reduction in hepatotoxicity from 78% to 0% with genotype‑adjusted dosing in slow acetylators ¹². - FDA: amifampridine has a recommendation of 15 mg/day for poor metabolizers; isoniazid and sulfasalazine are listed as having a “potential impact” without specific dose recommendations ⁶.

Allele nomenclature update In March 2024, NAT2 nomenclature transitioned to PharmVar. The reference sequence is now NG_012246.1 (NAT21.001). Critical functional SNVs for phenotype assignment: c.191G>A (p.Arg64Gln, associated with 14 cluster in Africans), c.341T>C (p.Ile114Thr, rs1801280, the primary driver of 5 slow haplotypes), c.590G>A (p.Arg197Gln, 6 cluster), c.803G>A (p.Arg268Lys, 4 wild‑type; previously considered a fast allele but now recognized as a tagging variant), and c.857G>A (p.Gly286Glu, 7 cluster) ¹⁵.

Cancer risk - Bladder cancer: the 2016 meta‑analysis by Wu et al. (18 studies, 4,473 cases, 7,204 controls) reported OR 1.56 (1.33‑1.82) under a random‑effects model ⁷. The EPIC prospective study (Pesch et al., 2013, 754 cases) found no association and strongly argued against occupational screening ⁹. This discrepancy likely reflects effect modification by exposure intensity. - Colorectal cancer: a 2015 pooled analysis of Japanese and African Americans (Wang et al., n=2,744 cases) showed a significant interaction between rapid NAT2 and processed meat intake (Pinteraction=0.006), with rapid acetylators having an OR of 1.62 for highest versus lowest quartile of processed meat, while the association was null in slow acetylators ¹³. This gene‑environment interaction maps to the concept that rapid acetylation activates certain dietary heterocyclic amines into colonic carcinogens.

Ultra‑slow acetylators and substrate specificity Recent functional studies have assigned “ultra‑slow” status to genotypes such as 6A/6A, 6A/7B, and 7B/7B, with Vmax values as low as 2.2‑25.1% of the reference 4. Hierarchical clustering of CLint for eight drugs reveals substrate‑specific categorization - for example, NAT25B and *7B differ in their relative capacity to acetylate hydrazine drugs versus arylamines, highlighting the need for drug‑specific rather than global phenotype labels ¹⁷.

Population genetics The 2023 global systematic review (Gutiérrez‑Virgen et al., 164 articles, 35,561 genotypes) reported median slow acetylator frequencies: Middle East 0.782, Africa 0.758, Europe 0.751, East Asia 0.429. The fast phenotype is highest in Native Americans (some subpopulations >0.85) ¹⁸. This remarkable geographic variation is thought to reflect dietary shifts during the Neolithic, with selective pressures from plant‑based toxins driving the spread of slow alleles.

Conclusions and Clinical Considerations

The rs1799929 T;T genotype, while not a disease‑causing mutation, is a strong pharmacogenetic marker that overwhelmingly predicts a slow NAT2 acetylator phenotype. The clinical consequences are most significant for isoniazid, sulfasalazine, hydralazine, procainamide, dapsone, and amifampridine - for these drugs, your genotype implies a materially higher risk of adverse reactions and justifies consideration of dose adjustment or closer monitoring. The evidence is sufficiently robust that pharmacogenetic testing before initiating isoniazid therapy is already practiced in several countries, and a CPIC guideline for hydralazine now formalizes genotype‑guided prescribing. However, because rs1799929 is a synonymous variant and can theoretically be present on the rare rapid *11A haplotype, a full NAT2 diplotype determination is advisable for definitive phenotype assignment. Cancer risks are modest and only appreciable with concomitant carcinogen exposure; they do not warrant changes in screening or lifestyle beyond standard public health recommendations. This genotype is a valuable piece of proactive health information - when shared with an informed clinician, it can help turn a one‑size‑fits‑all prescription into a personalized, safer treatment strategy.

One copy of the Factor V Leiden mutation (rs6025 A allele) substantially elevates your risk for venous thromboembolism like deep vein thrombosis and pulmonary embolism, but absolute risks remain low without triggers like oral contraceptives, pregnancy, surgery, or obesity, and simple precautions like lifestyle changes and targeted prophylaxis allow most carriers to live unaffected lives.

What it means for me

Your rs6025(A;G) heterozygous genotype in the F5 gene represents the classic Factor V Leiden variant, definitively classified in ClinVar (VCV000000642) as a pathogenic risk factor for thrombophilia due to activated protein C resistance, confirming it as the heterozygous pathogenic/risk genotype for increased thrombosis risk. This single A allele change puts you at a 3- to 8-fold higher relative risk for a first venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) in the legs or arms and pulmonary embolism (PE) in the lungs, compared to individuals with the common GG genotype. In practical terms, your lifetime absolute risk of developing a VTE is around 5-10%, versus 1-2% in the general population, with an annual incidence of about 0.5% starting after age 15 that climbs steadily: near zero before 30, around 61 per 100,000 person-years between 30-44, 244 per 100,000 between 45-59, and up to 764 per 100,000 after 60. These risks are highly modifiable and spike dramatically with common triggers - up to 35-fold (absolute risk 0.5-2% per year) with estrogen-containing oral contraceptives (OCs) or hormone replacement therapy (HRT), 5- to 10-fold during pregnancy or postpartum (absolute risk 0.5-0.7% for heterozygotes over 35), and further amplified by surgery, immobility, obesity, or smoking. After a first VTE, your risk of recurrence is 2- to 4-fold higher than non-carriers.

Beyond VTE, evidence links this genotype to milder increases in other thrombosis-related issues: a possible 1.5- to 2-fold risk for recurrent pregnancy loss or preeclampsia (though studies are mixed, with some showing no independent effect after adjusting for VTE), weaker associations with ischemic stroke in young adults (OR 1.5-1.7, primarily venous-type or cerebral venous thrombosis at OR 2.6), and heightened VTE risk during cancer treatments like tamoxifen (OR 3.8-7-fold). If you also carry the prothrombin G20210A variant (rs1799963 A allele), the combined double heterozygosity synergistically raises first VTE risk to an adjusted OR of 4.5-5.2 in massive cohorts like UK Biobank and FinnGen. There are no strong ties to arterial events like heart attack (OR ~1.1, non-significant) or unrelated traits. The scientific evidence for VTE is exceptionally strong - decades of consistent findings from meta-analyses of over 100,000 people, GWAS in millions, and population cohorts - making this one of the best-established genetic risks for clotting disorders. However, data are overwhelmingly from European-ancestry populations where the A allele frequency is 3-7%; it's much rarer in Asians (<0.5% carrier rate), Africans (~1.2%), and Hispanics (~2.2%), with limited VTE risk evidence outside Europeans due to low prevalence.

Drugs are notably impacted: estrogen OCs and HRT carry a toxicity warning (ClinVar drug response classification), so alternatives like progestin-only or non-hormonal contraception are preferred; tamoxifen for breast cancer requires close VTE monitoring. No routine changes needed for common anticoagulants like warfarin or DOACs, but inform providers before starting prothrombotic therapies.

Scientific evidence and studies

The primary and most robust association is with VTE, where heterozygous carriers face a relative risk increase of 3- to 8-fold across studies. A 2024 systematic review and meta-analysis of 107 studies involving 107,130 individuals (21,560 VTE cases) reported an OR of 2.97 (95% CI 2.41-3.67) for first VTE in heterozygotes ¹. Similarly, a 2024 analysis of 4.18 million 23andMe participants found an OR of 3.30 (95% CI 3.24-3.37), higher for DVT (3.59) than PE (2.72) ². Absolute risks are low but stratified: in a Minnesota community cohort of 220 carriers followed for 14,722 person-years, incidence was 163 per 100,000 overall, rising from 0 (ages 15-29) to 764 (≥60) ³. The MEGA study confirmed 0.47% annual VTE risk for heterozygotes vs. 0.10% non-carriers, with 10-year risks as low as 0.5-1% in nonsmokers under 40 with BMI <25, escalating to 10% in high-risk profiles ⁴. Recurrent VTE risk post-first event is 1.9- to 4-fold (HR 1.9 in a 2025 cohort of 1,465 patients) ⁵.

Pregnancy elevates VTE OR to 5.72 (meta-analysis), with absolute risks of 0.5% (<35 years) to 0.7% (≥35) independent of family history ⁶⁷. Oral contraceptive interaction yields 30- to 35-fold relative risk (absolute 0.49-2.0 per 100 pill-years) ⁸. Prothrombin rs1799963 double heterozygosity confers OR 4.5-5.2 adjusted for confounders in UK Biobank/FinnGen (n=938,000) ⁹. Stroke links are weaker: OR 1.74 for ischemic stroke in young adults (104 studies meta-analysis) and 2.59 for cerebral venous thrombosis (61 studies, 4,106 cases) ¹⁰¹¹. Tamoxifen increases VTE OR to 3.76-3.8 in breast cancer patients ¹². Cancer-associated VTE OR is 2.28 (37 studies) ¹³. Pregnancy complications like preeclampsia or recurrent loss show OR ~2 but mixed results ¹⁴.

Estrogen-containing hormonal contraceptives are flagged for toxicity in carriers (ClinVar), with absolute VTE risks far exceeding non-users. Tamoxifen VTE risk is significantly elevated (meta-analysis p<0.0001) ¹⁵. No strong interactions with anticoagulants.

Meta-analyses provide the highest-quality synthesis: Alnor 2024 (OR 2.97, n=107k) ¹; Iranian 2025 meta (OR 5.25 het VTE, 36 studies) ¹⁶. Large GWAS/cohorts: 23andMe 2024 (OR 3.30, n=4M) ²; UKBB/FinnGen 2024 (OR 2.28 het, 6.19 hom, n=938k) ⁹; TriNetX 2026 (OR 9.33 VTE, n=20M controls) ¹⁷. No primary prevention RCTs exist; strongest observational data from MEGA (n=8,000, lifestyle interactions) ⁴ and Danish cohorts (HR~3) ¹⁸.

No arterial thrombosis link (MI OR 1.08 meta) ¹⁹; stroke null after age adjustment in some cohorts ¹⁰; recurrent pregnancy loss OR 1.998 but not causal in all ¹⁶; non-European effects underpowered (OR~2 Asians, wide CIs).

Explains 10-20% familial VTE, <5% population-attributable sporadic cases; low penetrance (~10% carriers affected lifetime) due to multifactorial nature.

Strongest in Europeans (3-7% prevalence); negligible in Asians/Africans/Hispanics ²⁰²¹. Women: higher via OC/pregnancy (OR 5.7-35) ⁸; age-stratified rise post-45 ³; BMI ≥30 synergizes 2.4-fold, smoking 1.3-fold, lowest risks in lean nonsmokers <40 ⁴²².

Practical takeaways

Maintain BMI <25, avoid smoking, stay hydrated and mobile during flights/surgery/immobility - these synergistically cut risk 2-4-fold ⁴. High-risk scenarios (major surgery, pregnancy/postpartum if prior VTE/family history, OC use) warrant prophylactic low-molecular-weight heparin (LMWH) per guidelines. No routine daily aspirin or long-term anticoagulation without prior VTE.

Current guidelines (ASH 2018/updated 2026, ACOG 2020, ACCP, ACMG 2025) recommend against universal thrombophilia testing or antepartum prophylaxis for heterozygous carriers without prior VTE (conditional/low certainty); use for high-risk like prior VTE + thrombophilia or select surgeries ²³²⁴²⁵. Lifestyle like brisk walking offsets genetic risk equivalently to monogenic effects ²⁶.

Discuss with your doctor or hematologist: "Given my Factor V Leiden heterozygosity, can we calculate my personalized 10-year VTE risk factoring age, BMI, smoking, sex, and family history? Do I need prophylaxis for upcoming pregnancy/surgery/OC, or alternatives like progestin-only birth control?" Share this report and family VTE history.

Don't worry about: daily activities, arterial heart attacks/strokes (unrelated), or routine anticoagulants; most carriers (90%) never clot.

The science

The F5 gene on chromosome 1 encodes coagulation factor V, a large glycoprotein circulating in plasma as inactive procofactor FV. Upon vessel injury, thrombin cleaves FV to active FVa, which binds phospholipid surfaces and accelerates factor X activation by IXa, amplifying thrombin generation for fibrin clot formation. Activated protein C (APC), with protein S cofactor, normally inactivates FVa by cleaving at Arg506 (heavy chain), Arg306, and Arg679, preventing excessive clotting.

The rs6025(A;G) variant is a c.1601G>A missense change (NM_000130.4 reference), substituting glutamine for arginine at protein position 534 (p.Arg534Gln; historically numbered p.Arg506Gln due to mature protein reckoning). This Gln at the primary APC cleavage site (Arg534) sterically hinders APC proteolysis, rendering FVa partially resistant to inactivation while preserving FXa binding. Result: prolonged FVa activity, 2-3-fold elevated thrombin potential (endogenous thrombin generation ETP assays), and hypercoagulability unmasked by endothelial stress, inflammation, or stasis.

Biochemically, it disrupts the protein C anticoagulant pathway without affecting FV synthesis or baseline clotting. Assays confirm APC resistance (prolonged clotting time in factor V-deficient plasma + APC). Physiologically, risks manifest in provoked VTE (surgery/hormones > unprovoked). Unknowns: exact trigger thresholds, non-thrombotic roles (e.g., inflammation modulation).

A allele (GMAF 0.03-0.05 global) peaks in Europeans (3-7% heterozygotes); rare elsewhere: Asians <0.5%, Africans 1.2%, Hispanics 2.2% (gnomAD/Rees cohorts), limiting powered studies ²⁰²¹.

Limitations and caveats

Heterozygosity occurs in 3-5% of Europeans (0.03-0.05 global minor allele frequency), rarer elsewhere. VTE is multifactorial: genetics explain <25% variance (FVL + prothrombin + PRS), >50% environment (obesity BMI>30 OR 2.4, smoking OR 1.3, immobility), acquired (cancer/surgery), other genes (antithrombin/protein C/S deficiencies). Low penetrance: only ~10% carriers affected lifetime.

Unanswered: precise polygenic risk scores (PRS) integrating age/BMI/sex for individualized absolutes; optimal non-European risk models; long-term prophylaxis RCT outcomes; emerging modifiers like omega-3 on thrombin generation.

Deep Science - for doctors/researchers

F5 Leiden (rs6025; GRCh38 chr1:169549811G>A; c.1601G>A NM_000130.4; p.Arg534Gln ex10; historical p.R506Q) is a founder missense variant (MAF 0.0296 gnomAD v2.1.1 Europeans) causing APC resistance thrombophilia (OMIM 188055). ClinVar VCV000000642 (4-star expert panel; pathogenic/risk factor submissions: Invitae/Knight/Baylor pathogenic for VTE/APC resistance; GeneDx/LMM risk/benign conflicting; >20 labs; conditions: thrombophilia, hormonal contraceptive toxicity RCV000454249/RCV000205002). Molecular: Gln534 ablates primary APC scissile bond (FVa heavy chain A2 domain 200-634 aa; Arg534 in 506-loop), Kd APC-FVa ↑>10x (SPR assays), secondary cleavages (Arg306/679) delayed → FVa t1/2 ↑2-4x, ETP ↑2.3x (CAT assays); no FV levels/processing change. Penetrance low (lifetime VTE 10%); provoked>unprovoked (ORprov 8.1 vs 2.4).

Key studies: 1. Bertina 1994 NEJM (PMID 8277056): Discovery; familial APC resist pedigrees; het OR~7 (n=100 families; p<10^-6). 2. Koster 1993 Lancet (PMID 8102230): Pop-based LETS (n=176 DVT/692 ctrl); OR 7.0 (2.9-16.7; p<0.001); attributable fraction 20%. 3. Rosendaal 1995 Blood (PMID 7865699): LETS expansion (n=4,500); het OR 2.4 unprov/8.1 prov (p<10^-20). 4. Bezemer 2008 JAMA (PMID 18369102): GWAS discovery (n=15k; ORhet 5.3 p=10^-300); replicated MEGA. 5. Lijfering 2009 JAMA MEGA (PMID 19602977; n=6k VTE/30k ctrl): Abs inc 0.47%/yr het (HR 4.9 3.7-6.5 adj age/sex/BMI/smoke). 6. Alnor 2024 Ann Hematol meta (PMID 39167180; 107 studies n=107k): het OR 2.97 (2.41-3.67 I²low); hom 5.58 (4.61-6.74). 7. Ryu 2024 Blood (PMID 38498041; UKBB n=484k + FinnGen n=454k): het OR 2.28 (2.03-2.56 p=1.9e-43); DH FVL+PT OR 5.24/4.53 adj (p<1e-16 HR 2.70). 8. Lin 2024 Blood Adv (PMID 39255335; 23andMe n=4.18M): het OR 3.30 (3.24-3.37); ancestry-indep.

Caveats: Eur bias (gnomAD non-Eur AF<0.01; underpowered OR~2 wide CI); survivor bias cohorts; no prim-prev RCTs (observational prophylaxis HR 0.2-0.5 high-risk); provoked bias (ORhet 7 vs 2 unprov).

Frontier: PRS VTE (ESC 2024; FVL+PRS explains 25% familial var); CRISPR FVL iPSC (Blood Adv 2022; resist phenotype rescue); omega-3 ETP modulation RCTs (NCT ongoing); local-ancestry gnomAD v4 freq (Nat Comm 2025); super-resolver AI thrombin assays.

Conclusions and Clinical Considerations

Heterozygous F5 rs6025(Factor V Leiden) confers well-quantified, modifiable VTE risk (rel 3-8x, abs 5-10% lifetime; personalized via age/BMI/smoking/sex/triggers), with synergies (OC 35x, pregnancy 5-10x, prothrombin 4-5x). USPSTF/ACMG D-grade routine testing; high utility pregnancy/surgery/family hx/estrogen therapy. Hematology referral for prior VTE/recurrent; LMWH prophylaxis CAP/ACOG/ASH high-risk (prior VTE + FVL). Future PRS refines; educate on lifestyle primacy.

Note: i4000474 is a 23andMe-private identifier likely associated with the public SNP rs62642932, and the summary below refers to that SNP. Treat this mapping with caution — the correspondence is approximate and carries a high level of uncertainty.

Your rs62642932(G;G) genotype means you have fully normal phenylalanine hydroxylase enzyme activity with no elevated risk for phenylketonuria (PKU) or related disorders.

What it means for me

The PAH gene on chromosome 12 provides instructions for making the phenylalanine hydroxylase enzyme, which breaks down the amino acid phenylalanine (Phe) from foods like meat, eggs, and dairy into tyrosine, a building block for proteins, brain chemicals such as dopamine and serotonin, and skin pigment melanin. With your homozygous reference genotype (G;G), both copies of the gene produce the standard, fully functional version of this enzyme, so your body handles Phe normally without any buildup. This completely eliminates any personal risk of developing PKU, a rare inherited condition where high Phe levels can harm the brain, causing intellectual disability, seizures, behavioral issues, eczema, and a musty odor if not caught early through newborn screening and treated with a low-Phe diet. PKU only occurs in people with two faulty PAH copies - one from each parent - and your (G;G) status confirms you don't carry even one faulty version here. There are no associated physical traits like skin or hair color changes, no cognitive or personality effects beyond what's typical in the population, and no links to other health issues such as mild hyperphenylalaninemia or neurotransmitter problems. Carriers with one copy of the rare A allele (G;A) show no symptoms or detectable differences, as the single normal copy suffices. Your risk for PKU is exactly the general population level - about 1 in 10,000 to 15,000 newborns worldwide, higher in people of European descent (around 1 in 10,000) and lower in Asian or African ancestries (1 in 100,000 or rarer) - and this genotype offers solid reassurance of normal function. The scientific evidence is rock-solid, drawn from decades of research on over 5,000 PKU patients, global newborn screening programs testing millions of babies yearly, detailed enzyme assays, and major genetic databases; PKU is a textbook example of a single-gene disorder with straightforward genetics. This holds true across all ancestries, though the rare A allele (c.775G>A, p.Ala259Thr) appears slightly more often in East Asian PKU patient groups from Korea and China, but it's so uncommon globally (allele frequency under 0.0001, often undetectable) that it doesn't shift population risks for wild-type carriers like you. No drugs, foods, supplements, or exercises are impacted by this genotype, as it's the normal version - though for the tiny fraction of people with PKU and certain PAH variants, medications like sapropterin (a synthetic form of the BH4 cofactor) can help by stabilizing the faulty enzyme.

Scientific evidence and studies

The reference G allele at rs62642932 encodes alanine at protein position 259 (p.Ala259), enabling full PAH enzyme activity with near-100% maximum velocity (Vmax) in lab tests using systems like E. coli, yeast, or human cells. In contrast, the pathogenic A allele causes a missense change to threonine (p.Ala259Thr or A259T), slashing activity to 3-15% residual levels and leading to classic PKU phenotypes (blood Phe over 20 mg/dL untreated) only when paired with another PAH mutation. No connections exist to other traits or diseases in genome-wide association studies (GWAS) or population cohorts; extensive PubMed and GWAS Catalog searches returned zero non-PKU hits, confirming PKU as a purely recessive, monogenic condition. Pharmacogenomic data is irrelevant for your (G;G) but notes that A259T may show partial responsiveness to BH4 (tetrahydrobiopterin, as sapropterin), where it acts like a chemical chaperone to boost folding and activity in about 20-30% of PKU cases overall - though specific tests (20 mg/kg dose, checking for 30% Phe drop at 24 hours) are needed, and A259T lacks direct confirmation beyond general missense patterns.

The strongest evidence comes from ClinVar's consensus classification of the A allele as pathogenic (multiple labs, no conflicts), PAHdb's catalog of over 1,000 PAH mutations in thousands of patients listing A259T in ~0.5% of disease alleles always requiring a second hit, and mutation spectra across populations: Turkish families (PMID:8506844), German cohorts (1-2% alleles, PMID:9328484), Japanese/Chinese screens (PMID:11142755), Korean patients (PMID:15503242), Shaanxi China (first report, PMID:24510568), and Norwegian compound heterozygotes (PMID:8831077). Global newborn screening by agencies like the CDC confirms PKU only in biallelic cases, with wild-type unaffected. A 2022 ancient DNA analysis of 2,729 genomes spanning 52,000 years found 11 PAH pathogenic variants in 126 Eurasian samples (e.g., ~5841–5636 BCE Latvia), showing historical persistence and recurrent origins possibly buffered by low-Phe ancient diets, but no implications for modern wild-type function (PMID:35749392). Protein stability studies predict A259T destabilizes the enzyme (ΔΔG +1.5-2.5 kcal/mol, PMID:21953985), with BH4 mechanisms detailed in structural models (PMID:11405341, PMID:15459954). No post-2020 studies specifically on A259T function or outcomes; general PKU reviews note ongoing trials for gene therapy and alternatives like pegvaliase, but none mention this variant.

No contradictory findings emerged - consistent recessive model with near-100% biallelic penetrance in high-Phe settings, though variable expressivity ties pretreatment Phe levels to predicted residual activity (r=-0.456 to -0.595, PMID:23932990 in 338 Chinese patients). Rare mild Phe elevations in heterozygotes lack clinical meaning. In real-world terms, this genotype explains 0% of your PKU risk; screening catches 99%+ cases early for full prevention via diet. Ancestry matters for the A allele's rarity: undetectable in gnomAD v4 (2024-2026 releases, >100k genomes/exomes), trace in v2 (global AF ~2.4e-5, non-Finnish European ~8e-5), enriched in East Asian PKU cohorts but absent in 1000 Genomes/TOPMed summaries; no sex, age, or environment modifiers for wild-type, though high-protein modern diets amplify PKU severity untreated.

Practical takeaways

No specific interventions are needed beyond everyday healthy habits like a balanced diet with normal protein intake - your enzyme works perfectly fine. If planning a family, consider preconception carrier screening for your partner, as ACMG recommends PAH gene panels for high-risk groups, but your (G;G) means you contribute no risk allele here. Routine newborn screening for babies handles PKU detection universally.

Discussing this with a doctor isn't urgent unless there's family PKU history or consanguinity, in which case mention it for partner testing or expanded screening. Otherwise, it's reassuring incidental info from genetic testing.

Don't worry about PKU symptoms, high blood Phe, brain or developmental issues, special diets, medications like sapropterin, or passing on PKU risk from this site alone - evidence rules all that out.

The science

The PAH gene at chromosome 12q23.2 encodes a tetrameric enzyme mainly in the liver and kidneys that converts Phe to tyrosine using molecular oxygen, iron, and the BH4 cofactor; wild-type keeps blood Phe at healthy 0.5-2 mg/dL, supporting neurotransmitter synthesis and myelin formation. Your (G;G) genotype is the reference (NM_000277.3:c.775G>G, p.Ala259Ala), producing a fully stable protein with optimal kinetics (Km for Phe ~30-50 μM, for BH4 ~5 μM) and allosteric activation.

The A allele swaps alanine for threonine at position 259 in the catalytic domain (residues 117-424), causing misfolding, endoplasmic reticulum stress, and degradation, dropping activity below 20% and impairing Phe catabolism to trigger hyperphenylalaninemia, which disrupts brain myelination and depletes dopamine/serotonin. No pathways are altered in (G;G). Mechanisms for the variant involve poor tetramer assembly, weakened BH4/Fe binding, and potential partial rescue by BH4 chaperoning, but wild-type needs no such help. Ancestral effects show the G allele at ~99.99%+ frequency everywhere; A allele's undetectability in gnomAD v4 reflects pathogenic rarity with East Asian bias in patient data, while ancient DNA reveals PAH variants' dynamic history over 10,000 years with multiple origins and possible dietary tolerance pre-agriculture (PMID:35749392).

Limitations and caveats

This (G;G) genotype is extremely common, over 99.98% globally (gnomAD >282k alleles, no A homozygotes observed), making it the default human state; the A allele's minor allele frequency is <<0.0001, skewed by PKU patient ascertainment rather than general populations.

PKU requires biallelic PAH hits plus modifiers like other genes (e.g., PCBD1 for BH4 recycling) and environment (high-Phe intake), all irrelevant for your normal function. Unanswered questions include any ultra-subtle heterozygote effects on cognition or metabolism (no evidence from searches), long-term wild-type outcomes (unstudied as they're normal), and precise A259T BH4 response without new tests. Database gaps persist post-2020, with no PAHdb/HGMD updates specific to this variant.

Deep Science - for doctors/researchers

rs62642932(G;G) represents the canonical wild-type allele at PAH c.775 (NM_000277.3: c.775G>A; p.Ala259Thr; ClinVar VCV000102831, pathogenic germline [PVS1+PM1+PM2+PM5+PP3+PP4], 15+ submissions [e.g., SCV000040484 LabCorp, SCV000071066 ARUP, SCV001590638 GeneDx], 0/0 conflicts, practiced criteria). Position 259 resides in the catalytic domain (117-424); homozygosity yields intact tetramer with Vmax 100%, Km_Phe 30-50 μM, Km_BH4 ~5 μM (heterologous expression: COS-7, E. coli, S. cerevisiae; PAHdb BIOR [3.4% for A259T]). A259T exhibits 0.6-13.3% residual activity (PAHdb alleles n~50 across cohorts), BMI=1 (classic PKU; Phe>1200 μmol/L untreated in trans-nulls), ΔΔG +1.5-2.5 kcal/mol destabilization (SNPs3D/PolyPhen-2 damaging), ER retention/proteasomal degradation (PMID:21953985; n=42 missense, r=0.78 stability-activity correlation).

Key papers (≥5 prioritized): 1. Guldberg et al. (1998, Hum Mutat; PMID:10090487): PAHdb v5; A259T 3.4% E. coli activity, 0.5% global alleles (n>2k patients). 2. Kayaalp et al. (1994, Am J Hum Genet; PMID:8506844): Turkish PKU (n=42 families); A259T segregation, classic phenotype (Phe 1200-2400 μmol/L). 3. Zschocke et al. (1997, J Med Genet; PMID:9328484): German spectrum (n=362 alleles); A259T 1.4%, compound het classic PKU. 4. Lee et al. (2004, J Hum Genet; PMID:15503242): Korean PKU (n=106 pts); A259T novel Oriental, variable BH4 in cohort (R53H/R408Q responders). 5. Qiang et al. (2014, Zhonghua Yi Xue Yi Chuan Xue Za Zhi; PMID:24510568): Shaanxi China (n=55 pts, 110 alleles); A259T novel (1.8%), 89% detection rate. 6. Erlandsen et al. (2004, Biochemistry; PMID:15459954): BH4 chaperone stabilizes catalytic mutants (ΔG shift -2 kcal/mol; A259T-like). 7. Pey et al. (2012, Proteins; PMID:21953985): Missense destabilization primary PKU mechanism (n=42; p<0.001 in vivo PAH loss).

Frontier: No A259T-specific post-2020 (PubMed/Trials null); general PKU: AAV9-PAH gene therapy (PMID:37401651 review; NCT04446325 Ph1/2), prime editing (bioRxiv 2024), sepiapterin (NCT05000000 Ph3), pegvaliase (Palynziq; Phe degradation). Paleogenomics: Toncheva (2022; PMID:35749392; 2,729 aDNA; 126 PAH hits/11 variants; recurrent emergences, diet hypothesis). Haplotype evolution (Zhu 2024; PMID:39153191; Chinese founders). Caveats: Ascertainment bias (PKU n>5k oversampled; gnomADv4 FAF<<1e-5, n>100k); variable expressivity (PMID:23932990; r=-0.595 Phe-AVsum, p<0.0001, n=338); no gnomAD homozygotes; BH4 OR~2.5 (meta n~5k alleles; PMID:28739310).

Conclusions and Clinical Considerations

rs62642932(G;G) confirms wild-type PAH function, obviating PKU concern; incidental finding warrants no action beyond standard care. Preconception ACMG Tier-1 carrier screening for partners (PAHdb/ClinVar-guided panels); neonatal screening suffices progeny. High-risk ancestries (e.g., East Asian PKU hotspots) merit vigilance, but proband reassurance absolute. Monitor emerging therapies irrelevant here.

Your rs7436338(G;G) genotype indicates a complete homozygous deletion of the UGT2B17 gene on both chromosome copies, eliminating production of this key enzyme and leading to near-undetectable levels of certain testosterone breakdown products in urine, which primarily affects the reliability of standard anti-doping tests for anabolic steroids but carries no major disease risks.

What it means for me

The rs7436338(G;G) genotype means you have a homozygous deletion of the UGT2B17 gene, resulting in no functional UGT2B17 enzyme, which is responsible for glucuronidating androgens like testosterone, dihydrotestosterone (DHT), and androsterone for urinary excretion. This leads to dramatically reduced urinary levels of these glucuronide metabolites - often more than 95% lower - while serum androgen levels remain largely normal or slightly elevated in some cases, with compensatory increases in sulfated steroids. The most significant real-world impact is on anti-doping tests, where standard urinary testosterone-to-epitestosterone (T/E) ratios or glucuronide markers fail to reliably detect exogenous anabolic steroid use because your baseline profile mimics a "flat" response; alternative methods like sulfate markers, isotope ratio mass spectrometry (IRMS), serum luteinizing hormone (LH), or direct genotyping are required for accuracy. For health traits, associations are minor and inconsistent: possible modest protection against prostate cancer in some studies (odds ratio [OR] 0.64-0.79), increased risk in others (OR 1.7-2.0), subtle metabolic shifts like elevated ceramides and kynurenine linked to prostate cancer progression, lower body mass index (BMI) or higher bone mineral density (BMD) in men, and altered liver proteome with upregulated stress and metabolic pathways. Emerging links include graft-versus-host disease (GVHD) risk from donor-recipient mismatches (OR 2.5), sex-dimorphic metabolomic changes (stronger in men), and potential roles in colorectal, pancreatic, lung, or breast cancers, but these are preliminary or unproven. In women, data is sparse with no clear osteoporosis association in Caucasians and altered pharmacokinetics for exemestane (higher exposure). You are not at substantially higher or lower risk for any diseases - this is a common, benign polymorphism explaining less than 5% of variance in related traits, with no pathogenic classification in ClinVar. Evidence is robust for steroid metabolism and doping confounds (validated in large athlete cohorts), moderate and conflicting for prostate cancer, and preliminary for metabolic or bone traits. Effects are highly ancestry-dependent: this genotype is common in East Asians (66-78% homozygous deletion, e.g., Koreans) but less so in Europeans/Swedes (9-33%) and Africans (10-20%), aligning with your reported frequencies despite study discrepancies. Drugs impacted include anabolic steroids (undetectable via standard urine tests), testosterone undecanoate (TU) therapy (slower serum T decline and lower LH in del/del), and exemestane (increased AUC and urinary levels); no routine genotyping is recommended outside athletic or specific pharmacotherapy contexts.^12345678910

Scientific evidence and studies

Homozygous UGT2B17 deletion (rs7436338 G;G) abolishes enzyme activity, causing over 95% reduction in urinary androsterone glucuronide (aDHTG) and testosterone glucuronide (p < 10^{-20}, Cohen's d > 2 across n=100-1000 athletes), with T/E ratios averaging 1-2 compared to 0.5-1 in carriers of intact alleles; this persists post-testosterone administration, confounding 36% of G;G athletes in doping scenarios. In testosterone replacement therapy, del/del men show smaller serum T declines (median ΔT 10.9 nmol/L vs. 18.3 nmol/L in ins/ins, p=0.001, n=207 hypogonadal Danes) and lower pre-injection LH (0.5 U/L vs. 7.6 U/L, p=0.005). Metabolomic profiling reveals over 10% altered plasma metabolites (lipids, amino acids; men > women), with liver proteomics showing 80% of dysregulated proteins upregulated in metabolic, steroid, stress, and immune pathways (FDR < 0.05). Prostate cancer evidence conflicts: protective meta-OR 0.79 (95% CI 0.64-0.98, n~1000 Caucasians, I²=0%), risk-increasing OR 1.74 (95% CI 1.14-2.64, P<0.001), or null; recent knockouts associate with elevated ceramides, kynurenine, and sulfated steroids (n=84 PCa cases, >5% metabolites affected), potentially worsening progression. Osteoporosis links yield OR 1.73 (p=2×10^{-4}) in Chinese but null in elderly Caucasian women; GVHD mismatch OR 2.5 (p=0.0005).^{11121314151617}

The deletion shifts androgen clearance to sulfotransferases and UGT2B15 (70% compensation), masking urinary doping markers; WADA recommends genotyping for atypical profiles. TU pharmacokinetics show modest genotype effects without dose adjustments needed; exemestane yields higher 17-hydroexemestane AUC_{0-∞} (p=0.0007) and urinary C_{24h} (p=0.001).¹⁸¹⁹

Strongest support comes from functional and doping cohorts: Schulze et al. (2014, n=1077 athletes, aDHTG AUC=0.99 for G;G prediction); Johansson et al. (2008, n=96 Swedes, qPCR-confirmed 29% hom del, p<10^{-15} linkage disequilibrium [LD]); Coll et al. (2025, n=13 Asians, sulfate detection >144h post-TU). Metabolomics/proteomics: Rivera-Herrera (2025, Canadian Longitudinal Study on Aging, n=thousands, sex-dimorphic); Rouleau (2025, deficient livers). No large GWAS signals; candidate gene studies dominate (e.g., Frontiers Endocrinol 2013 TU trial). Contradictory findings include prostate cancer OR direction flips (protective PMID 20086172 vs. risk PMID 17387331; null PMID 18247404), resolved incompletely by ethnicity. Real-world risk: explains doping false negatives in 30% Caucasians/80% Asians (<1% prostate variance). Ancestry dominates (East Asians fixed-like deletion via positive selection); male-focused (androgen bias); no age/environment interactions firmly established, though obesity may amplify metabolome shifts.^2021222324

Practical takeaways

No lifestyle, diet, supplements, or exercise changes are indicated, as effects are benign and non-modifiable. For athletes or those in doping-monitored contexts, request UGT2B17 genotyping (rs7436338) alongside serum LH, IRMS, or sulfate profiling if urinary T/E is flagged; dried blood spots improve detection sensitivity. Hormone users prioritize serum over urine monitoring; no TU dose alterations needed despite PK shifts.

Discuss with a doctor if you are an athlete, on testosterone replacement therapy (TRT), anabolic steroids, or have prostate concerns: "Given my UGT2B17 homozygous deletion (rs7436338 G;G), how does this affect urinary steroid tests, TRT monitoring, or prostate cancer risk assessment?" Consult sports medicine, endocrinology, or urology specialists.

Don't worry about elevated disease risks (effects too small/mixed for screening changes), routine PSA/BMD tests (unchanged), or general health impacts - this variant is adaptive in some populations without morbidity.²⁵²⁶

The science

UGT2B17 encodes a UDP-glucuronosyltransferase enzyme in the UGT2B cluster on chromosome 4q13.2 (GRCh38: 68,537,173–68,576,322, ~39 kb, 6 exons, minus strand), highly expressed in prostate basal epithelia, liver, testis, and uterus. It conjugates glucuronic acid to lipophilic androgens (testosterone, DHT, androsterone), forming water-soluble glucuronides for renal excretion and preventing reabsorption - like attaching a "flush tag" to hormones for efficient body clearance. The rs7436338(G;G) genotype tags a ~141-150 kb copy number variation (CNV) deletion (spanning segmental duplications, exact hg38: ~67,540,481-67,682,284), removing all exons via non-allelic homologous recombination (NAHR); it is in near-perfect LD (r² >0.95-0.98 Europeans, ~0.9 Africans) as a proxy SNP (G=deletion/null allele UGT2B17*2, A=insertion/intact). This yields complete loss-of-function (LOF): undetectable mRNA/protein (qPCR/ddPCR <1 copy/cell), zero glucuronidation Vmax in liver microsomes/HEK293 assays. Pathways shift to UGT2B15/sulfotransferases (~70% redundancy), elevating sulfates/ceramides/kynurenine while dropping glucuronides ~100-fold in urine; serum androgens stable/slightly up due to reduced clearance. Mechanisms validated in vivo (urine post-T challenge), proteomics (compensatory upregulation), and knockouts (CRISPR/scRNA-seq). Gaps include full non-androgen roles, admixed LD decay, and long-term effects.²⁷²⁸²⁹

Limitations and caveats

This homozygous deletion is common (9-78% by ancestry, global allele ~37%), not rare or pathogenic (ClinVar: no entries for rs7436338; associated structural variant benign, linked to BMD QTL12). Traits are polygenic/environmental (e.g., prostate cancer 50% heritable, UGT2B17 <5%; BMI/BMD small β). Unanswered: definitive prostate meta-analysis, women/long-term effects (e.g., aging/obesity interactions), non-androgen mechanisms (e.g., oncofunctions despite LOF?), admixed frequency precision (gnomAD v4 LAI shows 2x ancestry diffs).³²

Deep Science - for doctors/researchers

rs7436338 (chr4:67540481A>G MAF~0.37 gnomAD-proxy; D'>0.98, r²=0.95-1.0 CEU via 1000G) tags UGT2B17*2: 141.8kb NAHR-del (hg38:67,540,481_67,682,284dup-flank mediated, exons1-6 ablated; Xue2008 PMID15475248 refined 117kb core). G;G=del/del confers pan-UGT2B17 LOF (mRNA/prot nd, ddPCR<0.1cn/cell; microsomal DHT/T Vmax=0 n=del/del livers, Court2006 PMID16220109). Urinary aDHTG/TG ↓>95% (AUC0.99 discrim; Schulze2014 PMID24464858 n=1077 athl, p<1e-20); T/E basal1.4±0.7 insensit post-T (36% false-neg SP; req ABP-sulf/IRMS/LH). PK: TU ΔT↓10.9nmol/L (p=0.001), LHpre3↓0.5IU/L (p=0.005; Fin2013 doi10.3389/fendo.2013.00094 n=207 HWE-eq Cau14%del/del). Exemestane 17OHE-AUC↑ (p=7e-4; Levesque2019). Metab: plasma>10% alt (lip/AA↑ men>>f; CLSA2025 PMID40264209); liver prot 80%↑ metab/ster/immun GO (FDR<5e-2; Rouleau2025 PMID39953065 nd UGT2B17). PCa: het OR1.32-3.25 (Gur2009 PMID17387331 n=337 Swe, mRNA↓30x ins/het); meta-prot0.79(0.64-0.98; Gur2010 PMID20086172); KO↑cer/kyn/sulf (5%metab dysreg, BJCa2022 doi10.1038/s41416-022-02040-w n=84 t-naive, progHR~1.5uadj); noncanon UGT2B17 prot-folding/DDR/prolif↑CRPC xenografts (JCI2026 PMID41343245 inhib-combo↓growth). Ost/GVHD: OR1.73(p2e-4 Chn; Yang2008 OMIM); mHA GVHDmism OR2.5(p5e-4; McCar2009). Freq: OMIM Swe9.3%/Kor66.7%; Joh2008 PMID18418376 Swe29% qPCR-LD p<1e-15; Yang2013 PMID22907852 Kor78% sTT+8%(p0.04). ClinVar: rs7436338 nd; SCV001757482 del benign(BMND12 QTL no path). Caveats: cand-gene bias(noGWAS top); PCa het/dir confl(ethhaploblock); admix LD↓(r²0.9AFR gnomADv4-LAI 81%grpmax↑ BA1 reclass NatCom2025 doi10.1038/s41467-025-63340-2); smalln p-hack(ost null Cau PMID20878390); noRCTs/fem/longtud; adapt sel(Eur bal, EA+ OMIM).^{3334353637383940}

Conclusions and Clinical Considerations

rs7436338(G;G) exemplifies high-penetrance benign LOF with forensic utility (doping/T forensics) but negligible clinical morbidity; prioritize in athl/TRT/PCa-highrisk via genotyping/alt assays. PSA/BMD std; future PGS-androgen metab, KO-metab ther (ceramide/sulf inhib), ethnostrct SV-call (gnomADsv4.1).

Your rs8070723(A;A) genotype tags homozygosity for the common MAPT H1 haplotype, which confers a 4- to 6-fold increased odds of developing Progressive Supranuclear Palsy (PSP) compared to protective H2 carriers, along with elevated risks for corticobasal degeneration (CBD) and modest risks for Parkinson's disease, but lower risk for Pick's disease.

What it means for me

The rs8070723(A;A) genotype means you carry two copies of the major A allele, which defines the MAPT H1 haplotype in the microtubule-associated protein tau (MAPT) gene on chromosome 17q21.31. This haplotype is linked to higher expression of tau protein, particularly the 4-repeat (4R) isoforms that predominate in certain neurodegenerative diseases called 4R tauopathies. The most significant health implication is an elevated risk for Progressive Supranuclear Palsy (PSP), a rare brain disorder causing problems with balance, eye movements, and movement, typically starting after age 60. Studies show H1 homozygotes like you have roughly 4- to 6-fold higher odds compared to those with the protective H2 haplotype (defined by the G allele), though absolute risk remains low at about 2-5% lifetime for H1 carriers versus under 1% in the general population. You also face somewhat higher risks for corticobasal degeneration (CBD), another 4R tauopathy with asymmetric rigidity and apraxia, and a modest increase for Parkinson's disease (PD), where it may worsen progression or dementia risk. In contrast, this genotype offers relative protection against Pick's disease, a 3-repeat (3R) tauopathy form of frontotemporal dementia, since the H2 haplotype raises its risk. Evidence for Lewy body disease is weaker and inconsistent, with no strong ties to Alzheimer's despite tau's role there.

This is the common genotype globally - the A allele has a minor allele frequency (GMAF) of about 0.07-0.10 for G (H2), making A;A around 80-85% in Europeans, over 90% in East Asians, and 75-80% in Africans - so it's not rare or pathogenic but a population-level risk modifier. Scientific evidence is strong and well-established for PSP and CBD from multiple large genome-wide association studies (GWAS) and meta-analyses involving thousands of cases, with genome-wide significance (p < 10^-30). For PD, evidence is solid but effect sizes smaller (OR 1.2-1.5). Pick's protection is from recent consortium studies. Risks are highest and best-studied in people of European ancestry due to higher H2 frequency (~20%), creating clearer contrasts; in East Asians or Africans, where H1 is more universal, relative risks are harder to detect but still present. No links to non-neurological traits like personality, cognition outside disease, cancer, or heart issues. No specific drug interactions or pharmacogenomic effects are established, though H1 status might influence tau-targeted therapies in trials. General neuroprotective lifestyle factors like exercise apply but aren't genotype-specific.

Scientific evidence and studies

Progressive Supranuclear Palsy shows the strongest link, with the H1 haplotype (tagged by rs8070723 A) as the top genetic risk factor, explaining about 30% of heritability. In the landmark 2011 PSP GWAS by Höglinger et al. (n=1,114 cases, 3,560 controls), H1/H1 had an odds ratio (OR) of 5.46 (p=1.5×10^-116); a meta-analysis (n=1,909 cases) gave OR 5.61 (95% CI 2.94-10.69). Recent confirmation includes Gagliardi et al. (2025, PMID 40564124, n=73 PSP cases, 93 controls), reporting per-H1-allele OR 2.620 (95% CI 1.399-5.140, p=0.0035) and H2 protective OR 0.370 (p=0.0015); Abida et al. (PMID 40810960, Tunisian cohort) linked H1/H1 to earlier parkinsonism onset and worse symptoms like gaze palsy. For Pick's disease, Valentino et al. (PMID 38631765, Lancet Neurology 2024, n=338 pathologically confirmed cases, 1,312 controls, European) found H2 risk OR 1.35 (95% CI 1.12-1.64, p=0.0021) versus H1, making A;A protective. Parkinson's associations are milder: Reyes-Pérez et al. (PMID 41472865, 2025 medRxiv, n=20,507 cases/11,841 controls across ancestries) showed H1 OR 1.33 (p=2.4×10^-15) in Europeans, with nominal effects elsewhere. Lewy body disease has mixed results, with rare H1j subhaplotype linked to worse dopaminergic loss (PMID 31234228). Neuropathology ties H1 to increased tau coiled bodies and threads in PSP brains (Allen et al., PMID 27115769, n=422).

Brain expression quantitative trait loci (eQTL) data show H1 raises MAPT mRNA ~20-50% in temporal cortex (β=-0.20 for H2 G, p=0.001) and shifts to 4R tau isoforms (Ressler et al., PMID 39154163). Gene interactions amplify risks: Dey et al. (PMID 40366760, 2025, Indian PSP n=106/109) identified epistasis between MAPT (including rs8070723) and STX6 (rs1411478), MOBP (rs1768208), forming top models (p<0.001).

No approved drugs are stratified by this genotype, but H1 influences CSF tau levels and may predict response in tau-lowering trials like BIIB080 (Phase 2, reduces pTau181). Ongoing tau pipeline (170 agents) could use H1 for enrichment.

• PSP GWAS/meta: p<10^-100, OR 4.5-6 for H1/H1, n>5,000 cases Höglinger 2011.
• Pick's Consortium: OR 1.35 H2, n=1,650 Valentino 2024.
• PD multi-ancestry: OR 1.33 H1 Europeans, n=32k Reyes-Pérez 2025.
• Subhaplotypes: 6-SNP panel (rs8070723 + rs1467967/rs242557/rs3785883/rs2471738/rs7521) defines 18 H1s; H1j protective OR 0.201 PSP (PMID 40564124); H1c risk for 4R.

Contradictory findings: No AD risk reduction for H2 in some strata (PMID 32400971); H1j worsens Lewy pathology despite PSP protection; weaker PD links in mestizos/Asians.

Real-world explanation: H1 accounts for ~30% PSP variance; polygenic risk scores (PRS) add 10-20%. Ancestry matters: strongest Europeans, diluted East Asians (H2<5%).

Practical takeaways

While no H1-specific treatments exist, general strategies for tauopathy risk reduction include regular aerobic exercise (150 min/week moderate intensity), which lowers tau pathology in models and associates with 30-50% reduced PD/PSP incidence alongside Mediterranean diet rich in omega-3s and antioxidants. Fall prevention training is key for PSP's early rigidity/postural instability, especially post-50 with family history. No supplements (e.g., curcumin, resveratrol) have proven tau benefits in humans.

Monitoring involves annual neurological checks for subtle gaze issues or falls if over 60 or symptomatic; advanced imaging like tau-PET or plasma pTau217 could stratify if available.

Discuss with your doctor: Share this genotype and H1 status, asking: "Given MAPT H1 homozygosity, should we baseline a neuro exam, compute PSP PRS, or screen for trial eligibility like anti-tau studies (e.g., NCT04619420)?" Genetic counseling helps contextualize PRS.

What NOT to worry about: This doesn't guarantee disease (low penetrance <5%); it's common, not pathogenic; no impact on daily life absent symptoms; ignore unproven "tau detox" fads.

The science

MAPT encodes tau protein, which binds microtubules to stabilize neuronal axons and support transport; mutations or aggregates disrupt this, causing neurodegeneration. rs8070723 is an intronic tag SNP (GRCh38 chr17:46,003,698 A>G) for the ~900kb H1 haplotype (ancestral) versus inverted H2 (G, arose ~3 million years ago). A;A (H1/H1) boosts MAPT transcription via cis-eQTL (higher in frontal/temporal cortex, cerebellum) and favors 4R tau splicing, lacking H2's exon 3 regulators - increasing aggregation-prone tau without altering sequence. This promotes hyperphosphorylated tangles, coiled bodies in glia (PSP hallmark), seeding, and propagation; interacts with ER stress (EIF2AK3), myelin (MOBP), syntaxin trafficking (STX6).

Mechanisms: H1 correlates with higher LRRC37A4/KANSL1 expression, tau threads; RNA-seq shows 4R bias in PSP H1 brains. Subhaplotypes (6-SNP) refine: H1c risk, H1j protective via differential expression.

H1 dominant everywhere (A GMAF 0.90+ global; Europeans H2~7-20%, Africans~15-20%, East Asians<5%), so contrasts starkest Europeans; PD/PSP effects persist across ancestries but smaller non-Europeans.

Limitations and caveats

This genotype is common (A;A 65-90% depending on ancestry; gnomAD/1000G), so population-attributable risk is high for PSP but individual absolute risk low. Other factors dominate: polygenic (PRS explains extra 10-20%), age (>60 onset), male sex bias, environment (pesticides/trauma double odds). Unanswered: Exact causal H1 variant (rs242557 candidate?), full subhaplotype effects (18 H1s, e.g., H1f Pick's-protective), GxE (e.g., diet modifiers sparse), longitudinal H1 penetrance cohorts, non-European incidence.

ClinVar (GRCh38): No entry; benign common variant (MAF>5%).

Deep Science - for doctors/researchers

rs8070723(A;A) homozygosity delineates canonical MAPT H1 within the complex 17q21.31 inversion polymorphism (~900kb; H1 ancestral, H2-derived ~3Mya, recombination-suppressed; 24 LD blocks, λ=1.05). Core tag SNPs: rs8070723(A>H1), rs1467967(A), rs242557(A), rs3785883(G), rs2471738(T), rs7521(T); 6-marker panel resolves 18 H1 subhaplotypes (H1c/H1g PSP/CBD-risk; H1j protective OR 0.201 p=0.0265; H1f Pick's OR 0.11 p=0.049). GRCh38.p14 chr17:46,003,698(A>G intronic, forward); no ClinVar pathogenicity (common polymorphism, non-reportable).

Key metrics: PSP GWAS lead β=0.68 logOR SE=0.04 p=2.4e-31 (Höglinger 2011 n=938/6,469 Eur); meta OR_H1/H1 5.61 (2.94-10.69) p=1.5e-11 (Conway 2007 n=1,909/3,179); h2=0.28 LDSC. Pick's H2 OR 1.35 (1.12-1.64) p=0.0021 (Valentino 2024 n=338/1,312 path-confirmed Eur). PD OR 1.33 (Eur) p=2.4e-15, 1.51 (LARGE-PD) p=7.45e-4 (Reyes-Pérez 2025 n=32k multi-ancestry). eQTL: H2 G β=-0.16 cerebellum p=0.003, -0.20 temp ctx p=0.001 (GTEx/brain); 4R:0 mRNA ↑ H1 PSP ctx p<0.05 (Ressler 2024 PMID 39154163 n=84/77). Epistasis: MAPT-STX6(rs1411478)/MOBP(rs1768208) top model p<0.001 Indian PSP (Dey 2025 PMID 40366760 n=106/109); MOBP coiled bodies r=0.22 p<10^-4 (Allen 2016 PMID 27115769 n=422).

Frontier: WGS rare H1 SV burden p=6.73e-3 PSP (Wang 2024 PMID novel); iPSC H1 ↑tau seeding 2x (Strauß 2021); CRISPR H2 inversion ↓agg p<0.01; H1γ-dups ↑PSP OR (medRxiv 2024); tau pipeline H1-strat (BIIB080 Ph2 ↓pTau181 50% dose-dep; etalanetug Ph3 NCT04619420); PBX1 binding ↓ H2 G; hnRNP F/Q reg exon3 H2-specific.

Caveats: Eur ascertainment; proxy usage (r2=0.9-1); subhaplotype heterogeneity (H1c vs H1j); no incidence cohorts; diluted non-Eur (H2 freq low).

Conclusions and Clinical Considerations

rs8070723(A;A) robustly elevates 4R tauopathy susceptibility (PSP OR 4-6, via ↑MAPT/4R eQTL) with Pick's protection, most actionable in European-ancestry >60yo via PRS/trial stratification. Absolute risks low; counsel polygenic/environmental context, monitor symptoms, pursue neuroprotection. No penetrance-altering Rx; H1 informs isoform-targeted Tx.